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ABSTRACT
Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) continue to be a sig-
nificant global burden, disproportionately affecting low- and middle-income countries
(LMICs). While much progress has been made in treating these epidemics, this has
led to a rise in liver complications, as patients on anti-retroviral therapies (to treat
HIV) and anti-TBs (to treat TB) are at an increased risk of drug-induced liver injury
(DILI). Therefore, patients on these medicines require consistent screening of liver
function. But, due to logistical barriers, gold standard DILI screening fails to be
executed at the point-of-care (POC) in LMICs. Therefore, this thesis aims to fill a
current and critical void in diagnosis and management of liver diseases in patients with
HIV/AIDS and TB in these settings where conventional diagnostic approaches are
prohibitively expensive. To address this gap in technology and patient care, we have
developed and optimized a robust, novel assay for on-site, POC monitoring of liver
health. We take an electrochemical approach to quantify the levels of alanine amino-
transferase, a key biomarker of liver function, from whole blood samples. We build
viii
a patient- and provider-centric platform for detection, aiming to minimize sample
preparation steps and simplify the user experience. Furthermore, we use a compu-
tational approach to explore the impact of our technology at the POC in LMICs,
quantifying both the efficacy and cost-effectiveness. Using this technology, health
care providers can assess patient liver health at the POC and make clinical decisions
in real time. In the field, this technology has the potential to impact HIV and TB
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This thesis aims to fill a current and critical void in diagnosis and management of
liver diseases in patients with HIV/AIDS and TB in low- and middle-income countries
(LMICs). In LMICs, conventional diagnostic approaches are prohibitively expensive.
The mortality and morbidity burden of HIV/AIDS and TB continues to be a
significant global challenge, with a disproportionate impact on populations of LMICs.
Currently, 36.9 million people are living with HIV/AIDS worldwide; 80% of which
live in LMICs (World Health Organization, 2019a). Annually, 1.5 million patients die
from TB; 98% of which live in LMICs (World Health Organization, 2020). This is
expected to worsen in the post-COVID world, as the HIV and TB challenges facing
LMICs are predicted to increase (Jewell et al., 2020).
As a result of the U.S. President’s Emergency Plan for AIDS Relief, the U.S.
spends $6.8 billion a year on the global HIV epidemic (Henry J Kaiser Family Foun-
dation, 2019b) and implementing partners have supported antiretroviral treatment
(ARTs) for more than 15 million people (US Aid, 2019). Additionally, the U.S. spends
$306 million each year on global efforts to prevent, detect and treat TB, reaching pa-
tients in more than 50 countries, including 20 of the 30 high burden countries (Henry
J Kaiser Family Foundation, 2019a).
While these efforts have helped to make significant gains in expanding access
to lifesaving HIV and TB medications, there is a systematic failure to monitor pa-
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tients on these medications for important side effects, such as drug-induced liver
injury (DILI) (Allain and Opare-Sem, 2016). For example, in retrospective studies
in Ethiopia, 32% of adults on ARTs showed varying levels of DILI, measured by an
increase in biomarker alanine aminotransferase (ALT) (Wondemagegn et al., 2013).
In retrospective studies in Uganda, 30% of adults with HIV showed markers of DILI,
also measured by an increase in ALT, due to TB medications (Ocama et al., 2008).
This is completely treatable, had these patients been monitored regularly for DILI
throughout their course of treatment.
To prevent DILI caused by both HIV and TB drugs, patients require consistent
liver function screening. Unfortunately for HIV and TB positive patients with limited
resources, the need for regular screening remains acute due to the scarcity of diagnostic
facilities offering blood biochemistry tests. Even when offered, a shortage of skilled
staff makes testing and interpretation of results challenging (Allain and Opare-Sem,
2016). Therefore, there is a critical gap in available diagnostic services to these
patients and an urgent need to develop a point-of-care liver test to address the growing
challenge.
1.2 Overarching thesis goals
In order to fill the current void in liver function monitoring, this thesis aims to de-
velop an affordable platform for point-of-care management of liver diseases in LMICs
through attempting the following goals:
• Develop and validate a novel, electrochemical assay to test for liver function
• Integrate novel assay into a portable platform, usable at the point-of-care and
• Demonstrate the effectiveness of portable platform in low-resource healthcare
settings
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We aim to simplify the diagnosis and management of liver diseases in low-resource
settings, so that patients all over the world can have access to necessary medical care.
1.2.1 Specific Aim 1
Specific Aim 1. Development of an assay to precisely quantify ALT from whole blood
samples
1.1 Development and validation of a novel, electrochemical assay capable of ALT
quantification over a large range of pathology
1.2 Optimization of quantitative ALT assay in blood samples
We developed a novel, electrochemical assay to quantify ALT in plasma samples
with high sensitivity, over a wide range of pathology. In collaboration with Dr. Fredric
Gordon at Lahey Medical Center, we validated this assay in patient plasma samples.
Our assay shows sensitivity two orders of magnitude greater than the next comparable
assay in literature. This assay serves as the basis of our point-of-care device.
1.2.2 Specific Aim 2
Specific Aim 2. Detection of ALT on a patient and provider centric platform.
2.1 Demonstration of a method for rapid blood plasma separation at the point-of-care
2.1a. Applications in ALT Sensing
2.1b. Applications in Malaria Rapid Diagnostics
2.2 Fabrication and optimization of functional paper-based device to perform both
blood separation and novel assay
2.3 Integration of user feedback from partners on the ground (teams focused on
Malaria in Thailand and Kenya, teams in Burundi focused on TB and HIV).
We developed a paper-and-plastic point-of-care device to precisely quantify ALT
concentrations from whole blood. We showed that this integrated device could suc-
cessfully extract plasma from whole blood and subsequently assay plasma for ALT.
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1.2.3 Specific Aim 3
Specific Aim 3. Implications for public health
3.1 Markov Model for an HIV and TB coinfected patient population to evaluate
efficacy of point-of-care liver testing
3.1a Cost-effectiveness analysis
3.2b Deterministic and probabilistic sensitivity analysis
We used a Markov Model to explore the impact of our technology at the point-of-
care in low-resource healthcare settings. We looked at a hypothetical cohort of HIV
and TB coinfected patients in rural Burundi and introduced liver function screening
to their treatment plan. We assessed the impacts on quality of life and medical costs
to the health-care system. We showed that point-of-care testing for liver function in
this patient population could greatly improve patient outcomes.
1.2.4 Looking Forward
We will accomplish these aims through both wet lab research and computational
modeling.
In chapter 2, we introduce liver function testing from a medical perspective, detail-
ing the importance of such tests, the gold standard methods, and our current ability
to do them at the point-of-care. We discuss the qualities of an ideal point-of-care test
and what academic labs have been doing to meet these criteria. We identify the gaps
that exist in the current point-of-care landscape and possible ways to address them.
In chapter 3, we present a novel assay to quantify ALT levels in plasma samples.
We begin with an explanation of our electrochemical assay scheme, along with proof-
of-concept validation experiments. We conclude with results from patient plasma
samples.
In chapter 4, we discuss methods for blood separation methods at the point-of-
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care. The chapter begins with a discussion of the gold-standard method, identifying
the pitfalls associated with translation to the point-of-care. Next, we discuss academic
methods of blood separation at the point-of-care. We use malaria rapid diagnostic
tests as a case study, and we present an integrated device to separate blood at the
point-of-care for this application.
In chapter 5, we put forward a fully integrated device for liver function testing
at the point-of-care. This is the first electrochemical point-of-care device to test for
liver function and represents a big step towards improving patient care in LMICs.
We discuss the device design, fabrication, and validation. We show proof-of-concept
data obtained from testing with plasma samples.
In chapter 6, we analyze the public health implications of liver function testing at
the point-of-care through a computation model. We look at a hypothetical cohort of
HIV/TB coinfected patients in Burundi and introduce monthly liver function screen-
ing to their treatment plan. We assess the impacts on quality of life and medical costs
to the health-care system. We include cost effectiveness and sensitivity analyses.
In the final chapter, chapter 7, we provide concluding remarks and discuss the
impact and innovation of the work described, limitations of the methods and results,
and future directions for the technology.
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Chapter 2
Background: tools for detection of liver
injury in low- and middle-income
countries
2.1 Liver diseases and the global burden
Liver disease1 poses a significant public health burden in both high- and low-income
countries, accounting for over 2 million annual, global deaths (Byass, 2014; Marcellin
and Kutala, 2018). Despite this significant mortality burden, liver diseases are his-
torically a neglected problem due to a lack of accurate evaluation of incidence and
prevalence statistics, as well as a lack of national and international programs targeting
these diseases (Cainelli, 2012; Marcellin and Kutala, 2018). A large portion of deaths
due to liver diseases can be treated (e.g. chronic hepatitis B), cured (e.g. chronic
hepatitis C), or prevented (e.g. acute liver failure due to medications) if prompt diag-
nosis is made; therefore, there is a need for appropriate funding and effective actions
towards this prompt diagnosis of liver disease, specifically in low- and middle- income
countries (LMICs).
2.1.1 Types of liver disease and required care
Liver disease is a general term referring to any disorder of the liver and includes many
conditions with a wide variety of causes. In high-income countries, liver disease is
1Sections of this chapter are adapted from (Moed and Zaman, 2019b)
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commonly caused by alcohol and obesity—resulting in conditions such as alcoholic
hepatitis and fatty liver disease. In LMICs, liver injury is usually caused by infectious
disease, such as infectious hepatitis (typically B or C) and the side effects of HIV and
TB medicines, which are toxic to the liver and result in drug-induced liver injury
(DILI). Hepatitis prevalence(Kilonzo et al., 2018), diagnosis(Allain and Opare-Sem,
2016; Cha et al., 2013; Morgan et al., 2017; Reipold et al., 2017; Ford et al., 2012),
and treatment (Ford et al., 2012; Nayagam et al., 2017; Shimakawa et al., 2018) are
well studied with much in the pipeline. DILI is more neglected in terms of burden
statistics, diagnostic options and the prevention plan for people in LMICs; there is a
pressing need for more data of this kind (Kelly et al., 2014).
In high-income countries, retrospective studies have shown the overall incidence
of ART-related hepatotoxicity ranges from 8.5% to 23%, while life-threatening events
occur at a rate of 2.6 per 100-person years (Núñez et al., 2001; Sulkowski et al.,
2000). Additionally, hepatotoxicity attributed to anti-TB drugs has been reported
in 5%-28% of people treated (Ramappa and Aithal, 2013). Shifting focus to LMICS,
there is little research on this topic and a potential for an increased burden due to
hepatotoxicity given the higher prevalence of both HIV and TB. In Ethiopia, 14-20%
of adults on ART show elevated serum liver enzymes as a marker of hepatocellular
injury. In Uganda, 30% of symptomatic patients with acute liver disease showed
markers of DILI due to TB medications (Ocama et al., 2008). Aside from this, the
data is sparse.
To prevent DILI, patients on HIV and TB medicines require consistent screening
of liver-function as part of their routine treatment. Unfortunately, for HIV and TB
positive patients with limited resources, the need for regular screening cannot be
met due to cost and logistics of available diagnostics that require extensive human,
infrastructural, and capital resources. Overall, there is a shortage of information
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on liver diseases of concern to HIV- and TB-infected individuals in LMICs due to
the scarcity of diagnostic facilities offering ultrasound, blood biochemistry, and liver
biopsy tests. Even when offered, these tests most likely cannot be carried out or
interpreted due to a severe shortage of skilled pathologists (Allain and Opare-Sem,
2016; Kelly et al., 2014).
2.2 The standard of care and barriers to implementation in
LMICs
Typically, liver health is evaluated through a liver function panel, measuring blood
levels of total protein, albumin, bilirubin, and liver enzymes. Elevations in serum
aminotransferases (alanine aminotransferase (ALT) and aspartate aminotransferase
(AST)), two enzymatic biomarkers of liver injury, are the most common abnormality
seen on liver function panels (Newsome et al., 2018) and enter the bloodstream due
to hepatocellular injury or death. Both transaminases are involved in the breakdown
of amino acids. ALT catalyzes the transfer of an amino group from alanine to alpha-
ketoglutarate, forming pyruvate and glutamate. AST catalyzes the transfer of an
amino group from aspartate to alpha-ketoglutarate, forming oxaloacetate. Generally,
when assaying for concentrations of ALT and AST, the enzymatic functions of these
enzymes are exploited for quantification. A ratio between concentrations of AST and
ALT, called the AST:ALT ratio, can be used to sort through root causes of liver
disease (Rej, 1990). For example, an AST:ALT ratio greater than 2 is indicative of
alcoholic liver disease. For cases of acute viral hepatitis, the AST:ALT ratio is usually
less than 1 (Rej, 1990).
ALT is found primarily in the liver, while AST is found in the liver, kidneys,
brain, heart and skeletal muscle. AST is also cleared from the bloodstream more
quickly than ALT. Therefore, to preliminarily detect hepatocellular injuries, the liver
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function panel can be narrowed to just ALT, as ALT is most specific to liver injuries
of all kinds (Lilford et al., 2013).
In high-income settings, the standard of care includes monitoring of ALT through
a venipuncture blood draw, followed by centrifugation to separate serum or plasma,
and then testing of the serum or plasma through an absorbance-based assay on a
large, automated, proprietary platform, shown in Figure 2·1 (Allain and Opare-Sem,
2016). In low-resource settings this testing is near impossible, failing at many critical
points throughout this process:
Figure 2·1: The standard of care for liver function testing in high
income settings involves monitoring alanine aminotransferase (ALT), a
biomarker associated with liver damage, through a venipuncture blood
draw, followed by centrifugation to separate serum or plasma, and test-
ing of serum or plasma through an absorbance-based assay on a large,
automated, proprietary platform. This is done at regular checkups for
HIV or TB patients. In low resource settings, two FDA-approved de-
vices exist in the landscape for POC testing of liver function. The
Roche Reflectron Plus system has the ability to measure 17 parameters
from whole blood and relies on venous blood draw along with complex
electronics. The device costs upwards of $6,000 with an additional cost
of $4.00 per test. The Alere Cholestech LDX is capable of using finger-
stick blood and costs upwards of $3,000 for the reader and $4.00 per
test.
To start, there is a lack of trained phlebotomists capable of drawing venipunc-
ture blood. If the blood is drawn, centrifuges are not usually available in district
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health settings, and when available, power cuts are frequent. Additionally, the large,
automated testing platform is usually stored in a centralized laboratory, hours away
from the sample collection site. This implies that blood must be drawn at the POC,
and then transported to the central facility where the test can be run. Because of
this, many samples are delayed or lost in transport to the centralized laboratories and
these labs generate delays of weeks or months between collecting samples and receiv-
ing results. This results in a major delay of clinical decision making and a substantial
loss to patient follow-up (Allain and Opare-Sem, 2016).
To combat some of these challenges, two FDA-approved devices exist in the land-
scape for point-of-care (POC) testing of liver function, shown in Figure 2·1. The
Roche Reflotron Plus system has the ability to measure 17 parameters from whole
blood but relies on venous blood draw along with complex electronics (Ref, 2019).
The device costs upwards of $6,000 with an additional cost of $4.00 per test. With
this system, the need for trained phlebotomists still poses an issue, along with the
prohibitive cost. On the other hand, the Alere Cholestech LDX is capable of using
fingerstick blood, allowing for healthcare workers with minimal training to collect the
sample. But, this device still costs upwards of $3,000 for the reader and $4.00 per
test, a prohibitively high number for many low resource settings (Cho, 2019).
These technologies, though designed for resource constrained settings, still fail to
be properly executed due to high cost, and lack of equipment, reagents, or trained
personnel (Byass, 2014; Marcellin and Kutala, 2018). This illustrates a critical gap
in the technologies developed and the realities on the ground. Cost is often still a
problem, as there is lack of finances for continuous support of the technologies. Ad-
ditionally, participatory research is often overlooked throughout the design process:
oftentimes technologies are developed for LMICs without incorporating perspectives
from local partners. So even with new, affordable technologies, local healthcare work-
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ers are still often untrained on how to use them, or the technology does not fit into the
existing healthcare infrastructure. The local landscape in LMICs varies widely and
there are differences in what would work in more urban areas versus smaller, rural
clinics. Therefore, local input and participatory research is crucial in technologies
developed for these settings.
For all of these reasons, there is a critical gap in available diagnostic services
to patients on hepatotoxic medicines, and there is an urgent need to work with the
providers and patients in these low resource settings to develop a robust, reliable, and
affordable platform to monitor liver function.
2.3 Desired qualities of a robust, implementable test
To ensure good uptake at the POC in LMICs, we must consider specific design targets,
which help new technologies to integrate into existing healthcare infrastructure. The
World Health Organization has enumerated these design targets into the ASSURED
criteria (Figure 2·2) as a benchmark for POC technologies: Affordable, Sensitive,
Specific, User-friendly, Rapid and Robust, Equipment free, Delivered to end-users
(Kosack et al., 2017). The benchtop technologies discussed previously (from Roche
and Alere) fall short with respect to these criteria, as they hit some but not all of
these targets. Technologies which hit these targets and address these short comings
will be more successful at the POC.
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Figure 2·2: WHO ASSURED Criteria for successful POC diagnostics
in LMICs. For diagnostic technologies to be successful in low-resource
settings, they must be affordable, specific, sensitive, user-friendly, rapid
and robust, equipment-free, and delivered to end users.
In addition to the ASSURED criteria, engineers must also consider ethics, social
inclusion, and the cultural aspects of the communities they target. Participatory
research and work with local partners can help to address these issues and shape the
ASSURED targets into quantifiable, attainable goals.
2.4 Academic movement towards a field deployable ALT test
Many groups have reported detection techniques for measurement of ALT from blood
samples through a variety of methods, including colorimetry, spectrophotometry,
chromatography and electrochemistry (Compagnone et al., 1992; Cooper et al., 1991;
Han et al., 2011; Huang et al., 2006; Kihara et al., 1984a; Kihara et al., 1984b; Mat-
suzawa and Katunuma, 1966; Mizutani et al., 1998; Moser et al., 1997; Ohmori et al.,
1981; Peguin et al., 1989; Pollock et al., 2012; Xuan et al., 2003). Some radiochemical
methods have historically been used, but less so now due to the known harmful im-
pact on human health (Garrison et al., 1988; Parvin et al., 1980; Perales et al., 1992).
These different technologies and methods, discussed in more detail below, each offer
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specific advantages but none of the assays discussed in this coming section have left
the academic realm to be commercialized and make a real impact in LMICs.
2.4.1 Colorimetry
Colorimetric assays for ALT rely on chemical reactions that produce color visible to
the naked eye, thereby allowing them to be very inexpensive and equipment free.
These assays are considered only semi-quantitative, as user interpretation can vary
across users and create some discrepancies. To overcome these discrepancies, colori-
metric assays are sometimes paired with a spectrophotometer or colorimeter for more
exact quantification of the color formation, eliminating error from user interpretation.
Colorimetric assays date back to the 1960s, with Matsuzawa and Katunama re-
porting a method for ALT detection in serum by coupling ALT activity to AST and
diazonium salt (Matsuzawa and Katunuma, 1966). In about 5 minutes at 37C, this
assay produced color according to extent of ALT activity. The final working volume
was 2mL. Although these specifications (rapid, small working volume) make this as-
say a great candidate for the POC, a spectrophotometer was used to measure optical
density and ALT concentration was calculated based on a concentration curve. Al-
though this assay showed promise, it still required extensive user sample-preparation
along with many manual steps and expensive equipment (spectrophotometer, cen-
trifuge, pipettes, etc.). Development towards a streamlined process to be used at the
POC was never pursued, a common trend among many of the assays discussed in this
section.
In another example, Lippi and Guidi reported a colorimetric method also based
on a diazonium salt and coupling enzymes (Lippi and Guidi, 1970). Similarly, for this
assay, there was no further development of an integrated platform to make this assay
useful at the POC. Additionally, Oki et al. put forward a biochip that could be used
at home or the bedside to quantify ALT from serum using a colorimetric reaction
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which generates a blue dye. The chip consisted of a mixing chip and a measurement
chip. Although this chip was somewhat integrated, it still required input of serum,
not whole blood, and therefore still required use of a centrifuge. This is a recurring
challenge and barrier to implementation at the point of care.
Notably, in a colorimetric assay from Pollock et al, a semi-quantitative ALT
scheme was used to group ALT concentration into three ranges: > 5x upper limit
of normal (ULN), 3-5x ULN, and < 3x ULN (Pollock et al., 2012; Pollock et al.,
2013; Vella et al., 2012; Diagnostics and of Pennsylvania, ). This assay was devel-
oped into an integrated paperfluidic platform that could be used with a drop of whole
blood. Additionally, no spectrophotometer was needed as the user ‘quantified’ the
colorimetric reaction by eye. This device underwent field testing at the Hospital for
Tropical Diseases in Ho Chi Min City, Vietnam, with an average of 91.5% agreement
with the gold standard method (Pollock et al., 2013). Although this assay found
great success in field testing, no information was found as to further development and
commercialization of this device post-2013.
2.4.2 Spectroscopy
Moving away from colorimetry due to the semi-quantitative nature, many research
groups began to shift towards spectrophotometric assays, capable of absolute quantifi-
cation over a wide measurement range including wavelengths invisible to the naked eye
(e.g. UV and IR light) (Rodgerson and Osberg, 1974; Henry et al., 1960; Hamada
and Ohkura, 1976; Fernández-Romero et al., 1990; Giusti et al., 1969). However,
spectrophotometric assays are generally not suitable for the POC as they require
expensive instrumentation, e.g. a spectrophotometer. Additionally, the sensitivity
of these assays can be compromised in blood samples, as spectrophotometry does
not discriminate between the sample of interest and other components in blood that
might absorb or fluoresce at the same wavelength.
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2.4.3 Chromatography
Quantification of ALT has also been demonstrated through chromatography, specif-
ically gas-liquid chromatography (Ohmori et al., 1981). Gas-liquid chromatography
offers the added advantage of direct quantification, meaning there is no need for cou-
pling enzymes or any other added components. Additionally, it can directly quantify
everything contained in the serum sample, not only the ALT or biomarker of inter-
est. That being said, chromatography is a slow process, requires extensive, expensive
equipment, and does not have the potential for a portable setup.
2.4.4 Electrochemistry
More recently, electrochemistry has been the focus of many developments in the field
due to the increased sensitivity of measurements and lack of expensive machinery
(Xuan et al., 2003; Thuy et al., 2016; Song et al., 2007; Peguin et al., 1989; Paráıso
et al., 2014; la Cour et al., 2016; Jamal et al., 2009; Huang et al., 2006; He and Chen,
1997; Han et al., 2011; Guadarrama-Fernández et al., 2018; Cooper et al., 1991).
Electrochemical assays have the potential to meet the ASSURED criteria and
integrate into the preexisting infrastructure at the POC in LIMICs. A great test
case for electrochemical testing at the POC is the glucometer, which requires only
an electrode chip and handheld electrochemical reader. Additionally, this involves
minimal interaction from the user. A glucometer ($30.00 for the reader, $0.14 per test
for the electrode chips) is a strong example of an electrochemical POC test: sensitive,
specific, user-friendly, low-cost, and deliverable to end users. A representative sample
of electrochemical ALT sensors are discussed in the following paragraphs.
For ALT detection, most electrochemical assays couple ALT to either an elec-
trode immobilized pyruvate oxidase (POX) or glutamate oxidase (GOX), relying on
subsequent detection of hydrogen peroxide (H2O2), as shown in Figure 2·3. These
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assays typically use platinum or palladium modified working electrodes coupled to
the secondary detection enzyme (POX or GOX) and demonstrate assay sensitivity in
the pico to nanoAmp range.
Figure 2·3: Methods for electrochemical detection of ALT. ALT cat-
alyzes the transamination of L-alanine and alpha-ketoglutarate to pyru-
vate and glutamate. Since neither glutamate or pyruvate are electro-
chemically active, ALT is coupled to either 1) pyruvate oxidase or 2)
glutamate oxidase, relying on subsequent detection of H202 at a mod-
ified electrode.
In an early example, Peguin et al demonstrated an electrochemical assay to detect
ALT levels by coupling ALT to POX and subsequently detecting the accumulating
peroxide directly at an electrode; however, the high overpotential needed to detect
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the peroxide directly lead to unwanted electron transfer when working with human
serum samples (Peguin et al., 1989). Easily oxidized species in blood (ex. ascorbic
acid, uric acid) reacted with the electrodes and caused interfering signals. Therefore,
research groups started to utilize a mediator (Figure 2·3), or an electrochemically
active species to act as a shuttle between the species being detected and the electrode.
With a mediator, detection at lower potentials is possible with less interference from
other analytes in blood. With this lesson in mind, Han et al. built on the work of
Peguin et al, demonstrating use of the Peguin assay with an electron transfer mediator
for more specific detection of ALT in serum at custom-modified gold electrodes (Han
et al., 2011). This assay was shown to detect clinically relevant ALT levels from
plasma samples with a linear range of 43-480 U/L and a limit of detection of 25 U/L.
Because this biosensor utilizes plasma samples, a centrifuge to separate whole blood
is still needed. Additionally, this assay was never formulated into an integrated device
that could be used at the POC, as it requires extensive user preparation, electricity,
and a computer; a setup that is not optimized for use in low-income settings.
More creatively, Moser et al. developed a miniaturized analysis system for rapid
detection of ALT using a GOX coupled electrochemical mechanism with a thin film
biosensor array for detection (Moser et al., 1997). Demonstrated in buffer solutions,
this assay can be executed in 4.5 minutes and requires 70uL of sample. The authors
believe that since the assay is not optical in nature, whole blood samples would suffice;
but this was never tested. This chip is fully integrated in terms of liquid handling
with on-chip pumps and mechanisms for analysis. This automation allows for less
variability and error between samples. That being said, this device was never tested
with blood or clinical samples and was never tested in the field.
In more recent literature, Paraiso et al. developed a novel bioelectrode for detec-
tion of ALT using POX and poly(4-aminophenol)/ 4-aminoantypyrine as mediators
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(Paráıso et al., 2014). These electrodes showed a low detection limit of 2.68∗10−5U/L
ALT, a promising, clinically relevant start. But, the electrodes were fabricated using
electropolymerization techniques, requiring many time-consuming preparation steps
such as washing, ultrasonicating, and deaerating. Additionally, the need for low tem-
perature storage conditions (8C) posed another barrier.
Thuy et al. developed a micro-platinum wire biosensor modified with GOX and
polymer layers, polypyrrole and Nafion, as mediators (Thuy et al., 2016). This group
showed a detection limit of 8.48 U/L ALT and a sensitivity of 0.059 nAmps/(U/L*mm2).
Preparation and maintenance of these electrodes was quite intensive, requiring many
dip-coating and baking (at 90C) steps as well as storage at -20C. Because of the need
for cold chain storage, these electrodes would not work feasibly at the POC in LMICs.
These sensors all vary in their specifications, trading off between improvements in
sensitivity, limit of detection, linear range, response time, sample volume, and fab-
rication complexity, summarized in Table 2.1. Overall though, none were developed
into integrated biosensors for use at the POC in LMICs. Though many of the assays
discussed sound promising, they fail to be translated to the POC as they require
expensive electrode fabrication techniques (Paráıso et al., 2014), centrifugation for
blood separation (Peguin et al., 1989; Hsueh Alan et al., 2012; Hsueh et al., 2011),
or cold chain storage (Thuy et al., 2016; Paráıso et al., 2014). When designing a
biosensor for liver function, one could keep in mind these common pitfalls, leveraging
them for success in translation to the field.
Therefore, although recent movement in this space has been positive, there is a










































































































































































































































































































2.5 Patents and clinical trials
An ongoing clinical trial through the University of Pennsylvania and Group K Di-
agnostics is testing the accuracy of a POC device to test liver function within 20
minutes. Their proposed device utilizes paper microfluidics and results in a colori-
metric response to liver enzymes in whole blood. A mobile phone application is used
to record the color change and output results. This study is still recruiting, as of the
publication of this thesis (Diagnostics and of Pennsylvania, ).
A patent titled “Systems and Methods for Electrochemical Aspartate Transami-
nase (AST) and Alanine Transaminase (ALT) Detection and Quantification” was filed
on February 28, 2019 (Hughes and Patwardhan, 2019). This patent puts forward an
integrated device for quantification of ALT and AST from a finger prick of whole
blood. The device should be capable of all process steps starting with sample collec-
tion through quantification but has only been demonstrated to quantify pyruvate at
this time. This proof of concept is promising, but quantification of ALT and AST
have yet to be demonstrated.
These clinical trials and patents are promising steps towards translation into the
field but still have yet to materialize and make a meaningful impact on patient treat-
ment.
2.6 Are the qualities of an implementable test met through
these existing methods?
The academic space relies heavily on four common detection methods for ALT: col-
orimetry, spectroscopy, chromatography, an electrochemistry. As discussed above,
these methods all have strong advantages and disadvantages when considering POC
applications.
Colorimetry is a great candidate for POC diagnostics, in that it meets all but one of
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the ASSURED criteria. Colorimetry is affordable, specific, user-friendly, rapid, equip-
ment free, and deliverable to end users. But, because colorimetry is semi-quantitative,
the method loses sensitivity as color can be interpreted differently between users.
Spectroscopy and chromatography offer improvements in quantitation and sensitiv-
ity, but require bulky, expensive equipment and cannot be delivered to end users at
low cost. Therefore, these are not great candidates for POC assays. Electrochem-
istry meets all of the ASSURED criteria, offering improvements in sensitivity (over
colorimetry) and portability (over spectroscopy/chromatography).
There has already been much movement in the electrochemical ALT detection
space (Xuan et al., 2003; Thuy et al., 2016; Song et al., 2007; Peguin et al., 1989;
Paráıso et al., 2014; la Cour et al., 2016; Jamal et al., 2009; Huang et al., 2006; He
and Chen, 1997; Han et al., 2011; Guadarrama-Fernández et al., 2018; Cooper et al.,
1991), but true integration into a POC device has not yet been pursued. Future
advances in this area should keep in mind the cost of device/electrodes, need for
cold chain storage, and use of whole blood over plasma. Throughout this thesis, we
will focus on these areas as we describe a novel approach for ALT sensing at the
point-of-care.
In this thesis, we strive to break this mold of dead-end lab science and to develop
an integrated POC platform for liver function testing in LMICs.
2.7 Discussion
Liver disease is a pressing public health problem in both high- and low-income coun-
tries and accounts for over 2 million annual, global deaths (Byass, 2014; Marcellin and
Kutala, 2018). Despite the significant mortality burden, liver diseases are historically
neglected due to a lack of accurate evaluation of incidence and prevalence statistics,
as well as a lack of national and international programs targeting these diseases (Mar-
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cellin and Kutala, 2018; Cainelli, 2012). Overall, there is a shortage of information on
liver diseases of concern to HIV- and TB-infected individuals in LMICs; the dominant
problem is the scarcity of diagnostic facilities offering liver function tests. Even when
offered, these tests cannot be carried out or interpreted due to a severe shortage of
skilled pathologists (Kelly et al., 2014; Allain and Opare-Sem, 2016).
Academic movement in the ALT detection space has been trending towards elec-
trochemistry, harnessing the ability to meet the WHO determined ASSURED criteria
and the potential to create an effective, integrated diagnostic. The academic realm
has developed ALT assays of many types, but none that have been integrated into
wholistic devices for use at the POC.
Therefore, there is a need for technologies that enable prompt diagnosis of liver
disease at the POC, specifically in low- and middle- income countries. This thesis
aims to fill this void with the development of an electrochemical, integrated point-of-
care device for liver function testing in LMICs. We will focus on the development of
a sensitive, specific assay and an affordable platform that is easily integrated into the
existing healthcare network, as it is user-friendly, equipment free, and accessible to
end users. We will keep in mind lessons we have learned from the literature and ensure
that our technology comprises of affordable electrodes, use of whole blood, and lack of
need for cold chain storage. By focusing on these weaknesses, we foresee the creation
of a device that is both usable at the POC in LMICs and readily commercializable.
We will incorporate input from our partners on the ground in LMICs at every step
along the way.
In the next chapter, we will demonstrate the use of an ALT assay that is sensitive,
specific, robust, and can be readily developed into a commercial test format. Subse-




A novel, electrochemical assay for ALT
quantification
3.1 Introduction
In the previous chapter, we discussed the current state of the art in electrochemical
liver function testing and the associated pitfalls. In this chapter, we present an assay
designed to overcome these common pitfalls and test for liver function at the point-
of-care.
HIV/AIDS 1 and TB continue to be significant global burdens, disproportionately
affecting low- and middle- income countries (LMICs). While much progress has been
made in treating these epidemics, these treatments have led to a rise in liver complica-
tions as patients on ARTs and anti-TBs are at an increased risk of drug induced liver
injury (DILI). Therefore, patients on these medicines require consistent screening of
liver function. Due to the logistical barriers discussed in chapter 2, gold standard
DILI screening fails to be executed at the point-of-care in LMICs. For this reason,
we have developed a low-cost assay that can be used to diagnose DILI. Keeping in
mind the ASSURED criteria, this chapter will focus on the development of an as-
say that is sensitive, specific, robust, and lends itself to be readily integrated into a
commercializable platform.
1Sections of this chapter are adapted from (Moed and Zaman, 2019a)
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3.1.1 Biomarker
Figure 3·1: Serum aminotransferase levels in various disease states.
Elevation of ALT can be as high as 10,000 U/L in patients with acute
toxic injury, such as acute ischemic insult or acetaminophen overdose.
Patients with acute viral hepatitis can present with ALT levels between
350-3,000 U/L. Alcoholic hepatitis elevates ALT to between 200-550
U/L while patients with chronic hepatitis present between 80-200 U/L,
compared to a baseline ALT value of 7-45 U/L (Johnston, 1999).
As discussed previously, alanine aminotransferase (ALT) is a primary biomarker used
for screening of DILI and will therefore be used as the basis of our assay, with the
goal of quantifying this biomarker both sensitively and specifically. When the liver
is injured, ALT leaves the damaged cells and enters the blood stream. For this
reason, ALT can be used as a measurement system and correlated with various disease
states, as shown in Figure 3·1 Within the specific context of DILI, ALT is elevated
according to the ranges and corresponding clinical decisions shown in Table 3.1. We
will use these various ranges to inspect the sensitivity and specificity of our novel
ALT assay, quantifying the accuracy with which this assay can be used for clinical
decision making.
3.1.2 Method of Detection
We will focus on the development of an electrochemical biosensor, due to the increased




































































































































































































































































































































































































in more detail in Chapter 2 (Chang et al., 2007; Jamal et al., 2009; la Cour et al.,
2016; Paráıso et al., 2014; Thuy et al., 2016).To develop a biosensor specifically
geared towards detecting ALT levels at the point of care, we must consider the four
main parts of a biosensor: 1) the biological sample input, 2) the bioreceptor, 3) the
electrical interface, and 4) the electronic medium (Grieshaber et al., 2008), as shown
in Figure 3·2.
Figure 3·2: Schematic of a Biosensor. Electrochemical biosensors
can be broken down into three main components: the 1) bioreceptor,
2) electrical interface, and the 3) electronic system. The bioreceptor
and electrical interface together make up the transducer, generating an
electrical signal from the biological processes.
Blood will be used as the biological sample input; ALT is present in blood in an
amount that corresponds to the degree of DILI (Table 3.1).
The ALT will act as the bioreceptor and work in combination with the electrodes,
which will serve as the electrical interface. In electrochemical biosensors, enzymes
are the predominant method for biorecognition, due mostly to their specific binding
capabilities and biocatalytic activity (Grieshaber et al., 2008). For these reasons
combined, we use ALT for biorecognition.
The chemical reactions that ensue are converted into an electrical signal and read
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out on an electronic medium, which is measured in one of three ways: generated
current (amperometric), potential or charge accumulation (potentiometric), or an
alteration in the conductive properties between electrodes (conductometric). In our
system, we use amperometric measurements, or amperometry, as it is a relatively fast
technique (Malhotra and Ali, 2017). Additionally, it is low cost, inert to ambient light,
highly selective and sensitive, and allows for easy fabrication and miniaturization of
electrodes.
To do this, we will use a three-electrode system consisting of a reference electrode,
a working electrode, and a counter electrode. The reference electrode is to be held
stable at a known potential. We will use silver/silver chloride (Ag/AgCl), as it is
inexpensive, nontoxic, and very stable (Grieshaber et al., 2008). The working elec-
trode, or redox electrode, serves as the transduction element in the chemical reaction,
while the counter electrode establishes a connection to the electrolytic solution so
that a voltage can be applied between the two. These two electrodes, working and
counter, need to be conductive and chemically stable; we will use carbon (graphite) as
it meets these requirements and is relatively low in cost (Grieshaber et al., 2008). As
is typical of amperometric measurements, we will apply a voltage between the work-
ing and reference electrodes, and the resulting current will be measured between the
counter and working electrodes. The applied potential can be adjusted to maximize
the response for the analyte of interest while minimizing the response for interfer-
ing analytes (Sadeghi, 2013). Additionally, we will employ a mediator, or electron
shuttle, to increase the specificity of the sensor. Figure 3·3 serves as an example of
how we will use a mediator to reduce electrode fouling and reduce the interference of
off-target electroactive compounds.
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Figure 3·3: Example assay schematic employing a mediator to detect
levels of NADH. NADH is utilized as a coenzyme and formed from
NAD+ in proportion to a biomolecule of interest. Next, NADH oxi-
dation reduces a mediator, which can be detected at an electrode at a
lower potential than NADH itself.
In this example schematic (Figure 3·3), the assay employs a mediator to detect
levels of NADH. Here, NADH was utilized as a coenzyme and formed from NAD+ in
proportion to a biomolecule of interest (Cardosi and Liu, 2012). Next, NADH oxida-
tion reduces a mediator, which can be detected at an electrode at a lower potential
than NADH itself. Without a mediator, the high electrode potentials needed to oxi-
dize NADH directly at an electrode could cause/allow other compounds in the blood
(i.e. ascorbic acid, uric acid, and acetaminophen) to transfer their electrons to the
electrode, compromise the selectivity of the system, and generate inaccurate readings.
Additionally, without a mediator, electrode fouling is also a problem: NAD+ adsorbs
onto the surface of the electrode and interacts directly with oxide functionalities on
its surface. This absorption results in a gradual blocking of the electrode (Cardosi
and Liu, 2012). Therefore, we use a mediator to reduce both electrode fouling and
the interference of electroactive compounds by transferring electrons to the electrode
29
surface at a much lower potential (Sadeghi, 2013).
3.1.3 Assay Design
We will use a novel electrochemical assay to quantify ALT in blood samples, as shown
in Figure 3·4. This assay serves as the basis of our system and therefore must be both
sensitive and specific to ALT activity. As discussed in the previous chapter, most
electrochemical ALT assays couple ALT to either an electrode immobilized pyruvate
oxidase (POX) or glutamate oxidase (GOX), relying on subsequent detection of hy-
drogen peroxide H2O2. These assays typically use platinum or palladium modified
working electrodes coupled to the secondary detection enzyme (POX or GOX) and
demonstrate assay sensitivity in the pico- to nano- Amp range. Here, we will take a
different approach, and instead of using a secondary enzyme, we will use a nonenzy-
matic reaction. This will ensure that our electrodes are cheaper to fabricate and do
not require cold chain storage.
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Figure 3·4: Schematic of reaction scheme. Reaction 1, 2, and 3 oc-
cur in series. In the first reaction, ALT catalyzes a reaction consum-
ing alpha-ketoglutarate and producing pyruvate. In reaction 2, alpha-
ketoglutarate and pyruvate react with hydrogen peroxide, reducing the
amount of peroxide in solution (Long and Halliwell, 2011). In this re-
action, pyruvate reacts more strongly and causes the bigger fluctuation
in final peroxide concentration. In reaction 3, the remaining peroxide
is detected at Prussian Blue modified electrodes. Overall, a decrease
in current is indicative of higher ALT concentrations; at higher ALT
levels, more pyruvate is produced, meaning more to react with peroxide
and less peroxide to react at the electrode.
Our assay is based on the ability to measure ALT levels in whole blood by lever-
aging enzymatic activity and monitoring the production of pyruvate. H2O2 is used
to quantify pyruvate as a proxy for ALT concentration, as shown in Figure 3·4. ALT
catalyzes the transamination of L-alanine and alpha-ketoglutarate to pyruvate and
glutamate. In a subsequent reaction, leftover alpha-ketoglutarate and newly formed
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pyruvate can react with hydrogen peroxide, depleting the concentration of peroxide
proportionally to the amount of alpha-ketoglutarate and pyruvate left in solution
(Long and Halliwell, 2011). The pyruvate reacts more strongly and therefore has
a greater impact on peroxide concentration (Long and Halliwell, 2012). Hydrogen
peroxide is then coupled to an electron transfer mediator, Prussian Blue (PB), and
detected amperometrically. Using this scheme, we will demonstrate an assay that is
fundamentally different than others described in the literature (Compagnone et al.,
1992; Cooper et al., 1991; la Cour et al., 2016; Pollock et al., 2012; Thuy et al., 2016;
Wang et al., 2016; Xuan et al., 2003). We will then use this novel assay to quantify
ALT at physiologically and pathologically relevant levels.
3.2 Materials and Methods
3.2.1 Reagents
Alanine, alpha-ketoglutarate, hydrogen peroxide, sodium hydroxide, and tris hy-
drochloride (Tris) were acquired from Sigma. Alanine aminotransferase from bovine
liver was acquired from Lee BioSolutions. Patient plasma samples were acquired from
Dr. Fredric Gordon at Lahey Hospital and Medical Center in Burlington, MA. Gold
Standard values were calculated via absorbance-based testing at Lahey Medical.
3.2.2 Experimental Protocols
All samples were prepared in 0.5 M Tris Buffer, pH 7.5. The pH of the buffer was
adjusted with sodium hydroxide. The final reagent concentrations were 50 mM Ala-
nine and 3 mM Alpha-ketoglutarate. 30% Hydrogen peroxide was diluted with Tris
Buffer 50:950µL. ALT concentrations varied throughout experiments, spanning the
range of physiologically relevant levels; these concentrations are noted appropriately.
Coupled reactions for electrochemistry experiments occur in in the following order:
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1) Incubation of plasma (50µL sample containing a range of ALT levels), alanine, and
AKG at 37C for 30 minutes, 2) Addition of hydrogen peroxide, incubation at room
temperature for 20 minutes.
3.2.3 Electrochemical Testing and Analysis
Screen printed electrodes (SPEs) were acquired from DropSens (DRP-710) and con-
tained a Prussian-Blue modified carbon electrode as the working electrode, carbon as
the counter, and silver silver-chloride as the reference. Amperometry was performed
with a commercial potentiostat (ChI 1200B) at -0.1V versus silver/silver-chloride and
resulting current was measured for 10 seconds. 50µL of solution was applied to the
electrode and readings were taken immediately at room temperature.
The current value at 10 seconds was used as the signal for that trace. For peroxide
studies, delta current is defined as the current due to Tris buffer subtracted from the
current signal at varying peroxide levels.
3.3 Results
To test the efficacy and feasibility of our assay, we first measured the hydrogen perox-
ide response on Prussian-Blue mediated electrodes. 50µL samples of varying peroxide
concentrations were pipetted onto the electrodes and detected amperometrically at
-0.1V versus silver/silver-chloride The measured current increased with increasing
hydrogen peroxide concentration, as shown in Figure 3·5a. At lower concentrations
of peroxide (<10mM) a linear increase in current was observed. This shows that
our electrode system functions as expected and that reaction 3 (Figure 3·4) works as
expected.
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Figure 3·5: Amperometric detection of Peroxide (A) and AKG, Pyru-
vate mixtures (B) at -0.1 V versus silver/silver-chloride. A). Blue
dots represent current measurements from pure peroxide solutions. B).
Black dots represent current measurements from mixtures of AKG and
Pyruvate, coupled to peroxide, showing the more pyruvate produces a
stronger change in the current signal.
As a next proof of concept, we tested the current response due to mixtures of
AKG and pyruvate with hydrogen peroxide, shown in Figure 3·5b. The x-axis shows
increasing pyruvate:AKG ratio, while the y-axis shows the impact on current. Pyru-
vate concentration has a more dramatic impact on current signal, due to the stronger
reaction kinetics between pyruvate and peroxide (Long and Halliwell, 2012) and there-
fore mixtures with more pyruvate more greatly impact the current. This shows that
reaction 2 (Figure 3·4) works as shown and that we can exploit this for further assay
development.
Figure 3·5b is important to focus on, as fully reacted samples containing ALT will
likely have a mixture of unreacted AKG and newly formed pyruvate. Therefore, this
is an important quantification: pyruvate concentration will dominate over AKG con-
centration during the hydrogen peroxide reaction. We expect that samples containing
more ALT will produce more pyruvate, and therefore show a greater amperometric
decay.
After proof-of-concept studies for reactions 3 (Figure 3·5a) and 2 (Figure 3·5b), we
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combined them with reaction 1 and performed the amperometric measurements. We
calculated current values by running our assay with plasma samples encompassing a
wide range of ALT concentrations. Figure 3·6 shows the relationship between current
and ALT concentration in patient plasma samples. With increasing ALT, current
decreases linearly.
Figure 3·6: Amperometric detection of ALT-coupled reactions at -0.1
V versus silver/silver-chloride in patient plasma samples. Blue shading
represents different clinically relevant levels of ALT, moving from grade
0 elevations (light blue- left) to grade 3 (dark blue- right). Solid line
represents the best fit from linear regression..
Figure 3·6 also shows the clinically relevant ranges of ALT concentrations in pa-
tients with pathology, represented with blue shading. For example, in the case of
hepatoxicity due to medications, Patients with ALT elevations of grade 2 or higher,
are generally switched to new medications. Patients with ALT elevations of grade 0
or 1 continue to be monitored regularly to ensure their ALT levels do not rise into the
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next zone. Based on the linear fit, we can quantify samples in each of the clinically
relevant zones.
Additionally, Figure 3·6 shows that between ALT concentrations of 14 and 307
U/L, the assay produces current proportional to ALT concentration, encompassing
a wide linear range of ALT concentrations with an R2 value of 0.983. Based on
this linear signal, current values can be used as an indicator of ALT concentrations in
solution. The allows us to calculate the sensitivity and limit of detection (Armbruster
and Pry, 2008) for this assay, according to the following equations:
Analytical Sensitivity =
Slope of the Standard Curve
Area of the Working Electrode
(3.1)
Limit of Detection = Limit of Blank + 1.645(SDlow concentration sample) (3.2)
where the limit of blank is defined as:
Limit of Blank = meanblank + 1.645(SDlow concentration sample) (3.3)
The slope of the standard curve (151.8 nAmps/(U/L)), was divided by the area of
the DropSens working electrode (diameter=4mm), and the analytical sensitivity was
found, according to equation 3.1, to be 12.08 nA/(U/L * mm2). Additionally, the
limit of detection, according to equation 3.2, to be 12.8 U/L ALT. In the following
section, we will compare this value against others published in the literature.
Next, we evaluated our assay performance compared to the gold standard method.
To do this, we used our assay and standard curve to quantify additional plasma
samples and compared them to the gold standard clinical zones, Figure 3.1. Each of
4 samples were tested 6 times. Though we only had access to a limited number of
plasma samples, this set of experiments gives us a relatively good idea of how our
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assay performs compared to the gold standard method.
A 2 by 2 table, Figure 5.2, was constructed to quantify how well our assay faired
in clinical decision-making power. Any samples that our assay quantified into the cor-
rect clinical decision were deemed in agreement with the gold standard. Any samples
that our assay quantified into a different clinical decision, were deemed in disagree-
ment with the gold standard. Based on this methodology, 23 samples quantified in
agreement with the gold standard, whereas one sample quantified in disagreement.
Table 3.2: Two by Two table showing bin placement accuracy of
plasma samples. We compared this work against the gold standard in
terms of clinical decision making; patients with ALT elevations greater
than or equal to grade 2 generally have their medications discontinued
or switched, whereas patients with ALT elevations less than grade 2 do
not (shown in Figure 3.1). Therefore, we quantified samples into these
bins to see if they would lead to correct clinical decisions by community
health workers using this tool.
Gold Standard Gold Standard
≥ Zone 2 < Zone 2
This work ≥ Zone 2 17 0
This work < Zone 2 1 6








true negatives+ false positives
(3.5)
Based on equations 3.4 and 3.5 respectively, the diagnostic sensitivity was calcu-
lated as 94% and the diagnostic specificity was calculated as 100%.
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3.4 Discussion
In this chapter, we have demonstrated a novel electrochemical ALT assay which is
sensitive (sensitivity 12.08 nA/(U/L*mm2)) over a wide linear range (14 U/L-307
U/L).
Compared to the other electrochemical ALT assays (discussed in ch2), our assay
shows increased analytical sensitivity (up to 105 fold) (Chang et al., 2007; He and
Chen, 1997; Jamal et al., 2009; Kihara et al., 1984a; Thuy et al., 2016) and a wider
linear range (Mizutani et al., 1998; Paráıso et al., 2014; Upadhyay et al., 2006),
shown in Table 5.3. We even show this increased sensitivity in a more complicated
sample matrix (plasma) than many in the literature; our analytical assay sensitivity
is potentially two full orders of magnitude higher than the next most sensitive assay
demonstrated in blood plasma or serum.
Though our assay appears more sensitive than others in the literature, there are
limitations to this comparison. Different electrodes and chemistries were used across
these studies, as well as different methods for the electrochemical and quantitative
analysis. For example, some assays used cyclic voltammetry while others used am-
perometry. The quantitative methods for analyzing traces varied between studies as
well. Future studies are needed to gauge the head-to-head differences in sensitivity.
The linear range of our assay is wide and covers the clinically relevant zones of
pathology seen in DILI. Additionally, the lower limit of detection shown here (12.8
U/L) is higher than other studies, but still clinically relevant in detecting stages of
liver disease, shown in Table 3. By using screen printed electrodes, we were able to
reduce the reaction volume significantly, also compared to other assays in Table 3.
While most studies couple ALT to other enzymatic reactions, the second reaction
shown here (AKG and H2O2) is non-enzymatic and eliminates the need for immo-






































































































































































































































































































































































































































mixing Prussian Blue into carbon ink—there is no need for dip-coating, doping or
other more complicated fabrication methods. Furthermore, this type of reaction is
less temperamental than an enzymatic process, allowing for greater electrode stability
and storage at room temperature. eliminating the need for a cold chain. By using
screen printed electrodes, we have decreased the sample and reagent volumes (up to
10 fold) needed to perform a complete test (Chang et al., 2007; Jamal et al., 2009;
Paráıso et al., 2014; Thuy et al., 2016). This reduction in sample and reagent volumes
is very important as we move towards translation to a POC device.
Our assay involves reasonable sample preparation when compared to other studies.
At the current stage, our assay involves the pipetting of different reagents at different
time points, similar to the assays demonstrated by Paraiso et al., and Jamal, et al.
(Paráıso et al., 2014; Jamal et al., 2009). Alternatively, other recent studies pipette
mixtures all together, at one time point (Chang et al., 2007; la Cour et al., 2016; Thuy
et al., 2016). Though our assay shows a longer time from start to finish than other
assays published in literature, a comparable amount of sample preparation is required
when compared to most recent literature. In chapter 5, we will focus on making this
assay more automated and user friendly, eliminating the need for pipetting at different
time points and making it more applicable at the point-of-care.
In terms of diagnostic performance, Table 5.2 showcases our ability to quantify
clinical samples with 94% sensitivity and 100% specificity. Though the number of
plasma samples tested is low, this data shows a promising proof of concept; our assay
could be used as a screening tool to aid in clinical decision making in the field. The
samples do not quantify perfectly, and expectedly, optimization is required. That
being said, samples quantify into the appropriate clinical grades and therefore lead
to correct clinical decisions.
This innovative method for quantifying ALT is meant to serve as a screening and
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triage tool for healthcare workers in low resource settings. Usually, these healthcare
workers make their decisions off of symptoms alone. This assay will provide them with
an additional piece of quantitative data to aid in their clinical decision making. At
this stage in development, limitations of this assay include its manual nature, meaning
users have to pipette different volumes at different time points throughout the process.
Additionally, the instability of hydrogen peroxide poses a great limitation, as the user
has to store the hydrogen peroxide stock in the refrigerator and pipette new dilutions
each time. These limitations are something we aim to overcome in the following
chapters. Future work includes a more extensive study with a greater number of
patient samples. Additionally, adaption of this assay to also work with aspartate
aminotransferase (AST), another common liver biomarker. With the AST:ALT ratio,
health care workers can be even more informed as to the status of their patients’ livers.
Overall, the preliminary data shown throughout this chapter demonstrates the
efficacy of this screening device, adding a relevant quantitative metric to the health-
care workers repertoire and narrowing down the selection of patients who require gold
standard testing. We have shown that our novel, electrochemical assay is sensitive,
specific, and works over a large range of ALT concentrations, correctly quantifying
clinical samples into the relevant diagnostic grades. Moving forward, this assay will
serve as the basis of our electrochemical device.
As we discussed before, many promising assays in the academic setting fail to
be translated to the POC as they require expensive electrode fabrication techniques
(Paráıso et al., 2014), centrifugation for blood separation (Hsueh Alan et al., 2012;
Hsueh et al., 2011; Peguin et al., 1989), and/or cold chain storage (Paráıso et al.,
2014; Thuy et al., 2016). The assay discussed here has the potential to overcome all
of these barriers at the POC, adapting blood separation to occur on-chip (ch 4) and
utilizing easily fabricated electrodes (ch 5). In the coming chapters, we will discuss
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each of these assets more in depth.
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Chapter 4
Methods for Blood Separation at the
Point-of-Care: An Interesting Use Case in
Malaria Diagnostics
4.1 Introduction
In the previous chapter, we discussed a quantitative, electrochemical assay to screen
for liver function from patient plasma samples. To successfully translate this assay
to the point-of-care (POC), we have validated a system to assay plasma from finger
prick samples of whole blood. By assaying directly from whole blood, we create a
technology which is accessible (A from the assured criteria) and delivered to end users
(D from the assured criteria). Therefore, in this chapter, we characterize, validate
and optimize a low-cost, easy-to-implement method for POC separation of plasma
from whole blood.
In order to use our novel alanine aminotransferase (ALT) assay (discussed in
chapter 3) to screen for liver health at the POC, we need to separate plasma from
whole blood; this helps to eliminate red blood cell (RBC) interference and make our
assay more accurate. Specifically, removal of red blood cells is important in ALT
quantification for two main reasons: 1) hemoglobin in RBCs react with hydrogen
peroxide in an off target reaction (Vallelian et al., 2008) and 2) high levels of RBC
lysis results in increased ALT activity (Koseoglu et al., 2011). Therefore, to decrease
background noise from off target interferents, RBCs must be removed prior to the
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ALT reaction.
Typically, centrifugation, the gold standard method, is used for blood separation.
But centrifugation requires highly trained personnel and large, expensive machinery.
Therefore, this method is not applicable in LMICs. The points of failure are outlined
in detail below:
• Centrifugation is prohibitively expensive, costing about 10-15,000 USD (Cen, )
• Centrifugation requires a power source. Therefore, centrifuges are usually only
found in a central laboratory, not at the patient POC. For POC clinics to use
a centrifuge, blood would need to be shipped to the central lab.
• Centrifugation requires a trained phlebotomist to draw venous blood. Trained
phlebotomists are not usually available at the POC in low resource settings.
For these reasons combined, in low resource settings blood separation through
centrifugation leads to delays in diagnostic tests and loss to patient follow up. We
aim to overcome these barriers for ALT testing by implementing blood separation at
the POC.
To avoid the need for centrifugation, researchers interested in developing systems
that work in LMICs have taken a wide range of approaches to separate plasma from
whole blood at the POC. These methods all aim to streamline the multistep centrifu-
gation process into one integrated platform for both separation and testing. Method-
ologies include microfluidic technologies (Karimi et al., 2019; Kuan et al., 2018; Maria
et al., 2017), hemagglutination techniques (Yang et al., 2012), and membrane stacking
in a vertical or lateral flow pattern (Keahey et al., ; Nie et al., 2010a).
Ultimately, we elected to incorporate membrane stacking, as it is the easiest to
implement and adds little assay time.
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4.1.1 Alternatives to Centrifugation
Alternatives to centrifugation include microfluidic technologies, hemagglutination
techniques, and membrane stacking. Here, we will discuss each of these methods
in detail.
Microfluidic technologies (Bhattacharya et al., 2007; Dimov et al., 2011; Karimi
et al., 2019; Kuan et al., 2018; Manz et al., 1990) make blood separation at the
POC more accessible as they can separate plasma with over 90% efficiency (Karimi
et al., 2019) in under 20 minutes (Kuan et al., 2018) without the need for expensive
machinery or power sources. But these technologies still incur major barriers when
implemented in low resource settings. Namely, these microfluidic devices are com-
plicated to use and require large blood volumes; meaning they still require a trained
phlebotomist.
Hemagglutination techniques (Yang et al., 2012), on the other hand, work to sep-
arate blood from volumes as small as finger prick, eliminating the need for a trained
phlebotomist. This method removes many of the barriers seen with microfluidic de-
vices, as they can be easily implemented on a single membrane. But, these techniques
only work with blood types A, B and AB. Therefore, people with blood type O ( 44%
of the population), would require a different method of separation (Yang et al., 2012),
making this method impractical for use at the POC in low resource settings.
Finally, membrane stacking has been shown to separate plasma from RBCs, with-
out the need for agglutinating antibodies and across all blood types (Keahey et al., ;
Nie et al., 2010b). This method is applicable to both lateral and vertical flow formats
and can be tweaked for different applications based on the types of paper and layers
used.
We move forward with membrane stacking for plasma separation, as this method
is quite easy to implement and requires very little added costs. Furthermore, it adds
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little assay time (< 2 minutes) to the final produce.
To study POC blood separation methods, we will briefly explore ALT applications
for liver health. We will then shift gears to look at malaria diagnostics, using malaria
rapid tests as a case study. Malaria diagnostics function as a great microcosm for the
barriers facing ALT testing and therefore function as a great case study; they both
share a similar barrier to implementation: blood separation is needed at the POC
without the use of a centrifuge. In the following sections, we will discuss the reasons
why.
4.2 Malaria Rapid Diagnostic Tests (RDTs): A Case Study
4.2.1 The Histidine-Rich Protein II Biomarker
Malaria, a life-threatening illness caused by parasites and transmitted through the
bites of infected female Anopheles mosquitos, disproportionately burdens low re-
source settings, such as the WHO African Region (World Health Organization, Global
Malaria Programme et al., 2015). In 2018, this region was the site of 93% of malaria
cases and 94% of malaria deaths (World Health Organization, Global Malaria Pro-
gramme et al., 2015).
The majority of the 228 million cases reported in 2018 were attributed to the P.
falciparum strain, with 99.7% of estimated malaria cases in the WHO African region
attributable to this species (World Health Organization, Global Malaria Programme
et al., 2015). P. falciparum infection is hallmarked by parasite production and secre-
tion of histidine-rich protein II (HRP2) (Pal et al., 2016) into the cytosol of RBCs.
As P. falciparum ruptures the host RBCs, cytosolic constituents, such as HRP2, are
released into the bloodstream. Therefore, in plasma from very sick, symptomatic
malaria patients, HRP2 can reach 100,000 ng/mL (Pal et al., 2016). To date, plasma
P. falciparum HRP2 is the most dependable and sensitive method to discriminate
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between patients with malaria and patients with different causes of febrile illness (Pal
et al., 2016).
4.2.2 Asymptomatic Malaria carriers and the Importance of Diagnostics
Malaria is one of the biggest barriers to global development and therefore a critical
target in the Sustainable Development Goals (SDGs). As a result of the global effort
to achieve the SDGs, there has been a significant global decrease in malaria inci-
dence over the last 20 years (World Health Organization, Global Malaria Programme
et al., 2015). As countries decrease their malaria burden and near malaria elimina-
tion, asymptomatic malaria carriers become an increasingly large part of the infection
reservoir. As a result, asymptomatic individuals contribute largely to forward trans-
mission, representing a grave concern for elimination programs (Das et al., 2017).
Therefore, to achieve elimination, it is imperative to identify and treat asymptomatic
carriers.
Most malaria infections are identified and treated at the POC. The WHO rec-
ommends prompt confirmation of all suspected malaria cases (febrile illness) through
RDTs. These tests are well suited for the POC as they are easy to use, run from
finger-prick blood, and require no expensive equipment. But, when asymptomatic
patients are tested by POC malaria RDTs, they oftentimes go undetected because
they carry low parasite densities and antigen levels (Landier et al., 2018). Therefore,
it is important to have POC diagnostics sensitive enough to identify these asymp-
tomatic patients with low-density infections. This will be a crucial step in malaria
elimination.
Central laboratories generally have the capability to run high sensitivity diagnostic
tests, but these tests are costly and require skilled workers. Additionally, the delay
in sample-to-answer time, caused by transport to the central lab, results in a loss
to patient follow up and makes screening and treatment an even greater challenge
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(Landier et al., 2018). Even less complicated molecular techniques with intermediate
sensitivity (i.e., loop amplification-mediated PCR (LAMP)) are currently still too
involved for application at the POC.
Therefore, there is an acute need to bridge the gap between sensitivity of central
lab diagnostics and accessibility of POC tests. This has resulted in a new generation
of RDTs, including the Alere Malaria Ag P. falciparum Ultra-Sensitive HRP2-based
ultrasensitive RDT (µRDT) (Das et al., 2017; Das et al., 2018; Landier et al., 2018;
Sinha et al., 2015; Vásquez et al., 2018).
Though these µRDTs have the capability to catch asymptomatic malaria patients
with low viral load, they cannot be readily implemented at the POC as their RDT
predecessors have been because they require plasma instead of whole blood. This is
because the HRP2 protein is also found in the RBC cytosol; therefore, RBCs must
be filtered out to avoid hemolysis and the introduction of noise (Pal et al., 2016).
Thus, malaria diagnostics and ALT screening share a similar barrier to implemen-
tation: blood separation is needed at the POC without the use of a centrifuge. To
achieve blood separation at the POC would be to bring µRDTs to the forefront of
malaria diagnosis, allowing for identification and treatment of asymptomatic carriers.
The remainder of this chapter focuses on the characterization and optimization of
a blood filtration system to be used at the POC. We will use the Alere µRDT as a
case study throughout.
4.3 Methods
As per the membrane stacking method, we have identified different types of plasma
separation membranes that work well with small volumes, as per criteria described
elsewhere (Nie et al., 2010a). We will test the three membranes identified: GF, GX,
and GR. The similarities and differences between these three membranes (summarized
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from here (Corporation, )) are shown in Table 4.1.
Table 4.1: Characteristics of plasma filtration membranes. Plasma
recovery is the amount of plasma through the filter. Membrane void
volume is the space within the solid phase of the medium that is oc-
cupied by the liquid sample, e.g. plasma. Based on membrane void
volume, the recommended blood volume is the recommended amount
by the manufacturer to generate rapid and consistent plasma separa-
tion with minimal hemolysis. Plasma separation time is the time to
flow through the membrane.
GF GX GR
Base Material Asymmetric polysulfone Asymmetric polysulfone Asymmetric polysulfone
Plasma Recovery >60% >60% >80%
Membrane Void Volume 1x 1 - 1.5x 2 - 2.5x
Recommended Blood Volume Capacity 20µ/cm2 20-30µ/cm2 30-40µ/cm2
Plasma Separation Time <2 minutes <2 minutes <2 minutes
With these membranes, we looked to compare 1. the efficiency of RBC capture, 2.
the efficiency of protein flow through 3. the ability to pass small amounts of plasma,
and the time to filtration (<2 minutes).
In the following work, we compare the filters in terms of these metrics.
4.3.1 ALT Device
As an initial proof of concept for sized based separation through the GF, GX, and
GR plasma membranes, fluorescent particles (Bangs Laboratories, Fishers, IN) were
used in a vertical flow system to allow for quantification of membrane capture effi-
ciency. We used 7.32 µm diameter Suncoast Yellow particles to represent RBCs. The
fluorescent particles, serial diluted in water, were used to create a calibration curve
on the spectrophotometer (SpectraMax M5) at 540nm excitation.
Each type of filter paper was cut to the size of a small petri dish and placed inside,
matte side up. 200µL of nanoparticle solution was pipetted onto the top of each filter
and after 6 minutes, the paper was pulled to the side, and, careful to keep the collected
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material on top of the filter, the flow through was collected. The fluorescence of the
flow through solution was measured on the spectrophotometer. Using the calibration
curve, a concentration of particles was calculated. Fluorescence of the solution before
filtration was used to calculate the proportion of particles that passed through the
filter. As further verification of nanoparticle entrapment, we imaged the top and
bottom of the plasma membrane under the confocal microscope (Olympus FV3000
Confocal Microscope).
Next, we moved to proof-of-concept for protein flow through, looking to ensure
that ALT would pass through the plasma membrane and not get trapped along with
the RBCs. ALT stock solution (Lee Biosolutions) was thawed and diluted to a con-
centration of 1100 U/L. Each type of filter paper was cut to the size of a small petri
dish and placed inside, matte side up. 200µL of protein solution was pipetted onto
the top of each filter and after 6 minutes, the paper was pulled to the side and flow
through was collected. The unfiltered solution and flow through solution from each
filter was run on an SDS page gel and visualized with Coomassie Blue.
As a final proof of concept, we looked to use the plasma membranes with a filter
paper backing (Whatman Grade 1), as opposed to petri dish, in a vertical flow setup.
This most-closely mimics how we envision the membrane to function in the final
device, with the filter paper backing representing the ALT reagent zone. We used
a 3-hole punch to cut the filter paper and plasma membranes into small circles and
stacked them on top of each other with the matte side of the plasma membrane facing
up and the filter paper behind. We pipetted 20µL of plasma onto the matte side of
the membrane, and after 2 minutes checked for wetness behind the membrane on the
filter paper. We did 20 repeats for each filter type and counted the amount of times
the filter paper had been wet.
Lastly, we tested the GF filter with whole blood samples and verified the capture
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efficiency using an auto blood analyzer (Hemavet 950FS). The GF membrane was
cut to the size of a small Petri dish (30 mm diameter) and placed inside, matte side
up. 200µL of human whole blood (Research Blood Components) was pipetted onto
the top of each filter and after 6 minutes, the paper was pulled to the side and flow
through was collected. The unfiltered whole blood and the flow through solution were
run on the auto blood analyzer and the proportion of blood cells through the filter
was calculated. For comparison, we centrifuged a blood sample and collected the
plasma after centrifugation. The uncentrifuged whole blood and post-centrifugation
plasma were run on the auto blood analyzer and the proportion of blood cells left in
the plasma was calculated.
4.3.2 Malaria Case Study
As we built this µRDT filtration device, we also considered engineering design, in
addition to blood filtration efficiency. We built a device that is easily integrate-able
with the current µRDT and fits within existing workstreams.
Therefore, after the ALT experiments outlined above verified that the filter worked
well and as expected, we moved onto engineering design.
First, we designed a plastic 3D printed device in SolidWorks, Figure 3. We wanted
a robust design to contain the GF plasma membrane and to fit in the blood collection
zone of the µRDT. The major constraint to design was integration into the existing
workflow, meaning that using the blood separation device should not majorly change
the existing dynamics for health workers performing the test. For this reason, we
discussed the design with our collaborators at the Mahidol-Oxford Tropical Medicine
Research Unit at each stage. The design was 3D printed (Prusa i3 MK3) and basic
usability was evaluated by having different users place the separation device into the
µRDT.
With a prototype device, we tested the µRDT s with whole blood samples to
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determine the optimal amount of blood needed to filter plasma through the device
without clogging or overwhelming the membrane. We used whole blood spiked with
HRP2 (provided graciously by Dr. David Sullivan, Johns Hopkins University) at
700ng/mL, knowing a positive test line would indicate that plasma got through the
membrane onto the µRDT test strip. We started with 5µL of blood, the amount
recommended by the manufacturer and swept downward looking at 4µL samples,
3µL samples, and 2µL samples. For each test strip, whole blood was applied to the
filtration device, and after 1 minute, the filter was removed, and the buffer solution
applied. The results were read after 15 minutes, according to manufacturer’s µRDT
instructions.
We checked visually if RBCs had gotten around the filter and onto the test strip.
Additionally, we checked each strip for the appearance of the positive test line. The
goal here was a balance between no RBCs and a positive control line. In this experi-
ment, we used a combination of µRDTs and conventional RDTs, based on what we
had in lab at the time.
Next, we tested the µRDTs with spiked whole blood samples near the µRDT
limit of detection (LOD). The LOD for µRDTs is 0.08ng/mL, as indicated by the
manufacturer. This is well within the range of parasite that an asymptomatic patient
would carry; for example, in asymptomatic children, circulating HRP2 concentration
has been shown as low as 0.1 to 1.0 ng/mL (Park et al., 2017).
We used whole blood samples spiked at 0.1ng/mL and applied both 4µL samples
and 3µL samples to the test strip. For each test strip, whole blood was applied
to the filtration device, and after 1 minute, the filter was removed, and the buffer
solution applied. The results were read after 15 minutes, in accordance with the
manufacturer’s instructions. We checked each strip for the appearance of the positive





First, we studied RBC capture efficiency of each membrane, using a nanoparticle
system as a proxy. Nanoparticle experiments showed that each membrane type,
GF, GX, and GR, had a similar capture efficiency towards RBC sized nanoparticles,
shown in Table 4.2. Each filter captured greater than 90% of the initial nanoparticles
in solution. In Figure 4·1, confocal images of the membrane after filtration show
that the top of the membrane (left), captured the red fluorescent nanoparticles. On
the bottom of the membrane (right), the autofluorescence of the porous membrane
structure is visible, while no red fluorescent particles are visible.
Table 4.2: Capture Efficiency of each membrane against RBC sized
fluorescent nanoparticles. The capture efficiency was calculated based
on a standard curve and the amount of fluorescent nanoparticles able
to flow through the plasma membrane in 6 minutes. N=3 replicates for
each membrane type.
Capture Efficiency
GF 92.74% +/- 0.03%
GX 92.65% +/- 0.00%
GR 91.57% +/- 0.04%
Next, we verified that the ALT protein was able to flow through the membrane.
The SDS page, Figure 4·2, shows that each membrane allowed for passage of the ALT
protein, as compared to unfiltered protein (column 2). Qualitatively, we see similar
amounts of protein flow through each filter.
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Figure 4·1: Confocal Images of the top and bottom of the plasma
membrane. Confocal images of the top (left) and bottom (right) of
the plasma separation membrane after the nanoparticle solution was
applied in a petri dish and allowed to filter through for 6 minutes.
Considering RBC capture efficiency and protein flow through, all three membranes
showed similar filtration properties to this point.
Next, we tested the membranes in a vertical flow setup most similar to how we
envision the final device. We looked at each membrane and the ability to filter 20µL
of plasma in less than 2 minutes. The GF and GR filters wet ≥95% of the filter paper
backings, while the GX only wet 60% of the filter paper backings, shown in Figure
4.3. Based on these results, we did not move forward with the GX filter.
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Figure 4·2: SDS Page gel stained with Coomassie Blue. This gel
captures the ALT in the flow-through solution after the membranes
filtered a protein solution for 6 minutes, compared to a control channel
where protein solution was not filtered through the membranes.
Though the GF and GR show similar filtration properties, the manufacturer states
that GR works best with large volumes while GF works best with small volumes.
Therefore, since we are looking at a small volume application, we chose to move
forward with GF.
Table 4.3: Plasma flow through the separation membrane in a vertical
setup onto a filter paper backing. Plasma flow through each filter, n=20
times, to see if filter paper backing became wet with 20µL of solution





We tested the RBC capture efficiency of the GF filter with whole blood samples,
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compared to centrifugation. The GF plasma paper captured 99.9% of the red blood
cells, performing comparably to centrifugation (also 99.9% RBC capture).
4.4.2 Malaria Case Study
CAD design and pictures of the prototype blood separation device are shown in Figure
4·3. Users (in this case members of the lab who had not played any role in designing
the device) agreed that the device was easy to insert and remove from the RDT. The
following experiments were all performed using the prototype device.
Figure 4·3: CAD design (A) and pictures (B,C) of blood separation
prototype device. Panel A shows a side and top view of the blood
separation device, designed in SolidWorks. GF filter paper goes at the
bottom of the extruding cylinder. Panels B and C show the 3D printed
part, with filter paper, nested inside of the RDT. The red solution is
food coloring, showing that liquid can pass through the filter paper and
wick onto the lateral flow strip.
First, we ran a positive control experiment to verify that HRP2 protein passed
through the membrane and flowed through the device. In these experiments, we also
visually verified that RBCs were not getting around the filter. Figure 4·4 shows that
the plasma does in fact wick through the filter membrane, allowing for HRP2 protein
to pass with it and resulting in a positive test line. At 2µL, a full positive test line
does not develop, indicating that 2 µL of whole blood is not enough to sufficiently
run the test. 5 µL overwhelms the filter and RBC get around it, shown in Figure
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4, right side. Therefore, 3-4 µL of blood is the optimal amount for the filter (4 µL
RDTs not shown).
Figure 4·4: RDT positive controls. RDTs run according to manu-
facturer’s instruction with spiked whole blood. 5 µL of whole blood is
enough to overwhelm the filter and allow RBCs to flow around it.
Next, we wanted to show that the µRDTs would still work with plasma close
to the limit of detection (LOD) of the µRDTs, and therefore be able to identify
asymptomatic malaria carriers. Figure 4·5 shows this proof of concept. With 3µLs of
blood, a positive test line appeared at 0.1ng/mL of HRP2. At 4µLs, a partial positive
test line appeared.
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Figure 4·5: CRDT limit of detection tests. RDTs run according to
manufacturer’s instruction with spiked whole blood. A positive and
partial positive control line appeared with 3µL and 4µL of blood, re-
spectively.
4.5 Discussion
Separation of plasma from whole blood samples is a non-trivial task at the POC in
low resource settings. Centrifugation, the gold standard method, fails for a variety
of reasons including the prohibitive costs, the necessity for large blood volumes, and
the need for trained phlebotomists. In this chapter, we have reported a method for
plasma separation at the POC and showed applications of this method in both liver
screening and malaria diagnostics.
We chose malaria as a case study for a blood separation device, working in collab-
oration with our partners at the Mahidol-Oxford Tropical Medicine Research Unit.
Malaria presents the perfect use case, connecting well with our overall goal of blood
separation at the POC; next generation µRDTs require plasma separation from whole
blood to sensitively detect HRP2, the biomarker of interest. These µRDTs have the
ability to detect low levels of parasite infection, when used with plasma, and therefore
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can identify asymptomatic malaria carriers. Identification and treatment of patients
in this population is a crucial step towards malaria elimination.
Thus, this presents a similar problem as posed to our ALT device: blood separation
is needed at the POC, without the use of a centrifuge.
Therefore, we set forward to make a usable filtration device that could be used in
concert with µRDTs to help detect asymptomatic malaria patients, a critical step in
achieving malaria elimination.
We used membrane stacking to test three membrane types from the Pall Corpo-
ration. Initial testing of three types of plasma membranes (GF, GX, GR) showed
similar functionality. This was true for both RBC capture efficiency and protein flow
through. In a vertical flow setup comparable to the final form, we looked at the
ability of each membrane to filter through small amounts of plasma in 2 minutes or
less. Here, the GX paper performed poorly, only having filtered plasma in 65% of the
devices tested. We eliminated GX based on this discovery. With GF and GR left,
we selected GF. Of the 3 membrane types, GF has the smallest void volume and the
lowest recommended blood volume per square centimeter (Table 4.1), meaning that
plasma from smaller amounts of blood are able to filter through. This is particularly
important when working with finger prick blood samples that yield finite amounts of
blood, a necessary constraint in both liver and malaria diagnostics.
With a membrane selected, we set out to make a filtration device compatible
with malaria µRDTs. We knew that easy integration into the existing health care
work infrastructure was essential for adoption of the technology. Therefore, ease of
use was a huge consideration in our engineering design. We tested ease of use with
various users (in this case, lab members who had not played any part in designing the
device) and incorporated feedback into the final design. In the future, we hope to put
this device in the hands of health workers in Uganda and Kenya, gathering firsthand
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feedback on the usability of the prototype as it fits into the existing workstreams.
With our device, we showed that plasma separation can be fully integrated into
the workflow of the µRDT, adding minimal time (1 minute) to the overall process.
We showed that even with very small volumes of blood, plasma was able to filter
through the membrane and wick down the length of the lateral flow strip, resulting in
a positive test line when minimal amounts of HRP2 were present. Even when tested
with HRP2 at 0.1 ng/mL, the minimum amount seen in asymptomatic children in
Uganda, a positive test line still appeared (Park et al., 2017).
Using this blood separation device combined with the Alere µRDT, asymptomatic
malaria carriers can be identified and treated, therefore shrinking the reservoir and
helping to block a large portion of disease transmission. This is crucial in malaria elim-
ination, as countries nearing elimination are left with a larger proportion of asymp-
tomatic cases. To identify these asymptomatic patients would be a huge step towards
treatment and reduction of the global malaria burden.
4.5.1 How this Relates to ALT Testing
Using the validated plasma separation membrane discussed here, we move one step
closer to creating a technology to screen for ALT and liver function at the POC,
ensuring that it can be accessible (A from the assured criteria) and delivered to end
users (D from the assured criteria). Blood separation in an integrated platform as it
relates to liver function testing will be discussed more fully in the next chapter.
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Chapter 5
Device Design: Towards a fully integrated
technology to screen for liver function at
the point-of-care
5.1 Introduction
In the previous chapters, we demonstrated a novel ALT assay for quantitative, point-
of-care detection (ch3) as well as a point-of-care method for rapidly separating plasma
from whole blood (ch4). This chapter focuses on the integration of these two parts,
as we develop and validate a platform technology for liver enzyme testing in low
resource settings. Here, our overarching goal is to develop a technology that meets
the ASSURED criteria. We will focus specifically on a platform that is affordable
and equipment free. We will discuss this in the context of device design, fabrication,
and functionality.
5.1.1 Device Design
A schematic of the device operation is shown in Figure 5·1a. To use, the blood
filtration arm is folded over and a drop of blood (shown in red) from fingerprick is
placed onto the plasma separation paper, Figure 5·1b. Plasma filters through onto
the ALT reaction zone (2 minutes), and then the blood filtration arm is torn along the
perforated line. The ALT reaction proceeds in this first filter paper zone, consuming
the dried alanine (ALA) and alpha-ketoglutarate (AKG) and forming pyruvate.
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Next, the ALT reaction zone is wet with a reconstituted hydrogen peroxide adduct
(for stability), Figure 5·1c, which reacts with the AKG and the formed pyruvate.
Finally, Figure 5·1d, the screen printed electrodes (SPEs) are folded over onto the
peroxide reaction zone and immediately inserted into the electrochemical reader for
analysis.
As we move through this chapter, we will discuss this device in terms of the
following 4 zones: 1. Blood filter zone, 2. ALT reaction zone, 3. Peroxide reaction
zone, and 4. Detection zone.
Figure 5·1: Device Design. A) Full device before use. B) To use, the
blood filtration arm is folded over and a drop of blood (shown in red) is
placed onto the plasma separation paper. Plasma filters through onto
the ALT reaction zone (2 minutes), and then the blood filtration arm
is ripped off along the perforated line. The ALT reaction proceeds in
this first filter paper zone. C) Next, a reconstituted hydrogen peroxide
adduct is dropped onto the reaction zone (5 drops). Here, the urea
peroxide reacts with the alpha-ketoglutarate and the formed pyruvate.
D) Finally, the SPEs are folded over onto the reaction pad and inserted




8.5” by 11” self-adhesive plastic laminate (Fellowes #5221502) provides the base ma-
terial for the ALT devices. This plastic laminate serves as the hydrophobic barrier,
surrounding filter paper (Whatman Grade 3) reaction pads, which serve as the hy-
drophilic surface, as shown in Figure 5·2a. Stencils for both the plastic, Figure 5·2b,
and paper were designed in a vector graphics software (Inkscape) and cut to shape
using a laser cutting tool (Epilog Laser 60W). Blood plasma membrane (Pall Cor-
poration GF) was also laser cut to the same shape and size as the filter paper. The
stencil included perforated cuts in the laminate to allow for easy folding of the device
during construction, as well as easy tear off of device arms during usage.
The plastic cut outs were folded to shape and the 3 holes were filled accordingly:
1 with filter paper disc, 1 with plasma separation paper, and 1 with screen printed
electrodes. Step by step fabrication is shown in Figure 5·2c.
For the remainder of the chapter, we will discuss the device functionality in each
of the four zones: blood filter zone, ALT reaction zone, peroxide reaction zone, and
detection zone, as shown in Figure 5·2a.
The plasma separation zone consists of plasma separation membrane GF (Pall
Corporation). The selection and validation of this membrane was discussed in detail
in chapter 4.
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Figure 5·2: Device Fabrication. A) Device schematic and example
shows the 4 zones of the device: the blood filtration arm, ALT reaction
pad, peroxide dropper, and detection arm. B) Laser cutting stencils
used to fabricate the device. C) Fabrication steps for the device. The
light grey circle represents the plasma separation paper, while the dark
grey circles represent filter paper. i. Device, sticky side up, pre-folding.
ii. The blood filter arm is assembled. The plasma paper is lined up
with the hole and the sticky sides of the laminate are folded towards
each other. iii. The detection arm is assembled. The electrodes are
lined up with the hole and the sticky sides of the laminate are folded
towards each other. iv. shows what the device looks like to this point.
v. The ALT reaction zone is assembled. Filter paper is lined up with
the hole and the sticky side of the laminate is folded toward the other.
vi. Fully assembled device.
The ALT reaction zone consists of dried reagents ALA and AKG. In this reaction
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zone, the filter paper disc was wet with a mixture of alanine and alpha-ketoglutarate
(50 mM Alanine and 3 mM Alpha-ketoglutarate) and allowed to dry overnight.
The peroxide reaction zone consists of a stable adduct of hydrogen peroxide. In
this reaction zone, 24mg of urea peroxide powder is reconstituted in 1 mL of a buffer
solution.
In the detection zone, screen printed electrodes (DropSens 710) are used for current
detection.
5.2.2 Device Functionality, proof-of-concepts
5.2.3 1 and 2. Blood Filter and ALT Reaction Zones
To verify that the ALT reagents could reconstitute in the presence of plasma, we
tested the dried reagents in the ALT reaction zone with a pyruvate indicator (Abcam
Pyruvate Assay Kit Ab65342). First, we added patient plasma with varying levels
of ALT to the top of the blood filter arm, allowing it to wick through to the ALT
zone, initiating the ALT reaction. We incubated the samples at 37C for 30 minutes,
allowing for the ALT reaction to proceed and result in the formation of pyruvate.
After the incubation, we performed the Abcam Pyruvate assay, adding the reagents
to the filter paper circle. We allowed the filter paper circles to incubate for 30 minutes
in the dark.
In the presence of pyruvate, the Abcam indicator should turn pink. A pink filter
paper circle indicates that the ALT reaction proceeded with the dried ALA and AKG,
reconstituted in patient plasma.
For stability experiments, the same Abcam pyruvate indicator was used. On day 1,
we dried ALA and AKG onto the ALT reaction zone. We stored these strips (predried
strips) at room temperature, protected from light. On each day, we reconstituted
the reaction well with ALT spiked into buffer. We tested 3 strips on each day and
compared them to 3 strips dried the morning of the experiment. We compared the
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resulting fluorescent signal between the 3 predried strips and the 3 freshly dried strips,
normalizing the signal from the predried strips to the signal form the fresh dried strips.
5.2.4 3. Peroxide Reaction Zone
In order to identify which approach may make this assay translatable, we explored
different formulations of hydrogen peroxide, selecting for types with the greatest sta-
bility. As the assay is highly dependent on peroxide concentration, this step is es-
sential in ensuring assay quality. Here, we have considered two types of hydrogen
peroxide powders: sodium percarbonate and urea peroxide. Both of these formula-
tions release hydrogen peroxide when dissolved in solution. Our goal was to identify
a stable formulation that would dissolve quickly upon reconstitution.
To test the feasibility of using these different formulations, we first measured the
hydrogen peroxide dose response on Prussian-Blue mediated electrodes. Peroxide
dilutions ranging from 0 to 250 mM were made from both sodium bicarbonate and
urea peroxide powder.
50µL samples of each of the varying peroxide concentrations were used in the
following electrochemical measurements:
Screen printed electrodes (SPEs) were acquired from DropSens (DRP-710) and
contained a Prussian-Blue modified carbon electrode as the working electrode, carbon
as the counter counter, and silver silver-chloride as the reference electrode. Amper-
ometry was performed with a commercial potentiostat (ChI 1200B) at -0.1V versus
silver/silver-chloride and resulting current was measured for 10 seconds. 50µL of
solution was applied to the electrode and readings were taken immediately at room
temperature. An average current over the last 3 data points of each trace was cal-
culated (last .3 seconds): this value was then used as the signal for that trace. For
peroxide studies, delta current is defined as the current due to Tris buffer subtracted
from the current signal at varying peroxide levels. For stability experiments, a stock
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of urea peroxide (recommended to be stored from 2-8C) was kept on the bench at
room temperature and a control stock of urea peroxide was kept in the refrigerator.
Sodium Bicarbonate was not evaluated for bench top stability, as the manufacturer
recommends bench storage. Each day, a sample was taken from each stock, dissolved
in water at 0.5M and 1M. Amperometry was performed with a commercial poten-
tiostat (ChI 1200B) at -0.1V versus silver/silver-chloride and resulting current was
measured for 1 second.
For solubility experiments, we dissolved the peroxide powders into water by shak-
ing. We started with 5 mg into 1 mL of water, increasing in 5 mg increments. We
timed how long the pellets took to dissolve completely into the water, with a maxi-
mum time constraint of 5 minutes.
5.2.5 4. Zone of Detection
We fabricated screen printed electrodes in-house, shown in Figure 5·3, using a protocol
previously established in our lab (Wu and Zaman, 2015). Briefly, circular hydrophobic
barriers were patterned onto filter paper (Whatman Grade-1) using a commercial
wax printer. The wax-patterned papers were melted on a hot plate for 3 min at
100C. Then, carbon, carbon mediated Prussian Blue, and silver/silver-chloride ink
were screen-printed using a homemade stencil. The stencil pattern was designed in
Inkscape and cut into cellulose acetate film, 0.05mm thick, with a laser cutter. The
patterned sheets were dried on a hot plate for 20 min at 65C, and then cooled at
room temperature for 1 minute. An example electrode chip is shown in Figure 5·3b.
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Figure 5·3: Homemade SPEs schematic (A) and example (B). The
SPEs consist of a wax printed hydrophobic barrier, a carbon counter
electrode, a carbon/Prussian blue working electrode, and a silver/silver
chloride reference electrode.
Experiments using the homemade SPEs were performed in a manner that was
similar to the DropSens SPEs. Amperometry was performed with a commercial
potentiostat (ChI 1200B) at -0.1V versus silver/silver-chloride and resulting current
was measured for 1 second. 50µL of solution was applied to the electrode and readings
were taken immediately at room temperature. An average current over the last 3 data
points of each trace was calculated: this value was then used as the signal for that
trace. For peroxide studies, delta current is defined as the current due to Tris buffer
subtracted from the current signal at varying peroxide levels.
5.2.6 Device Functionality, full device
ALA and AKG were dried onto the filter paper circle in the ALT reaction zone.
Next, the device is used as shown in Figure 1. To recap, upon the addition of 50 µL
of plasma, the ALT reaction proceeds in this first filter paper zone, consuming the
dried alanine (ALA) and alpha-ketoglutarate (AKG) and forming pyruvate. Next,
the ALT reaction zone was wet with 70 µL reconstituted urea peroxide, which reacts
with the AKG and the formed pyruvate. Finally, the SPEs were folded over onto the
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peroxide reaction zone and immediately inserted into the electrochemical reader for
analysis.
5.3 Results
5.3.1 Device Functionality, proof-of-concepts
5.3.2 1 and 2. Blood Filter and ALT Reaction Zones
Plasma samples were pipetted onto the GF plasma separation membrane (blood filtra-
tion zone) and allowed to wick through to the filter paper circle (ALT reaction zone)
for 2 minutes. The device was then placed onto a hot plate at 37C and incubated for
30 minutes.
The plasma was enough to reconstitute the ALA and AKG, initiating the ALT
reaction, as shown with the commercial pyruvate indicator, Figure 5·4. With in-
creasing ALT, the indicator increases in intensity, correlating with a greater pyruvate
concentration.
Figure 5·4: Proof-of-concept data for blood filtration and ALT reac-
tion zone. Plasma samples were pipetted on top of the plasma sep-
aration membrane and allowed to wick through for 2 minutes. The
device was then placed onto a hot plate at 37C and incubated for 30
minutes. The plasma initiated the ALT reaction, as shown with the
pink pyruvate indicator.
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We tested the stability of the ALT reaction zone over 32 days, shown in Figure
5·5. We compared the fluorescent signal generated from the predried reagent strips to
a control batch of freshly dried reagent strips made that day. If the strips remained
stable at room temperature, we expected the normalized signal (predried to fresh dried
strips) to remain at 1 over the duration of the experiment. Though we experienced
a great amount of variability between test strips, we saw that the predried reagent
strips produced a similar signal to the control reagent strips. Though further testing
into the sources of variability is still ongoing, we concluded that the ALT reaction
pad is stable at room temperature over 1 month.
Figure 5·5: Stability of ALA and AKG dried onto paper over 32 days.
Error bars represent the standard deviation from 3 data points.
5.3.3 3. Peroxide Reaction Zone
For both the sodium bicarbonate and urea peroxide, the measured current increased
with increasing hydrogen peroxide concentration, as shown compared to pure hydro-
gen peroxide in Figure 5·6.
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Figure 5·6: Amperometric detection of Sodium Percarbonate and
Urea Peroxide, compared to liquid hydrogen peroxide at -0.1V versus
silver/silver-chloride. Dose response with DropSens Electrodes.
Next, we looked at the stability of these formulations at room temperature, with
the goal to eliminate any need for cold chain storage. Per the manufacturer’s rec-
ommendation, sodium bicarbonate can be stored at room temperature while urea
peroxide should be stored from 2-8C. Therefore, for these stability experiments, we
focused primarily on the urea peroxide compound to see if it could withstand condi-
tions at room temperature.
We then compared the amperometric signal generated from urea peroxide stored
at room temperature with a control batch of urea peroxide stored in the refrigerator.
Over a 60-day period, we saw that the benchtop urea peroxide generated a similar
signal to the refrigerated batch, as shown in Table 5.1. Therefore, we concluded that
urea peroxide was stable at room temperature, over a period of 60 days, and would
not require cold chain storage within that period.
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Table 5.1: Stability of Urea Peroxide stored at room temperature
versus refrigerated conditions.
Room Temperature Conditions Refrigerated Conditions (Manufacturer Recommended) % CV
Average Signal (µAmps) Average Signal (µAmps)
Low Peroxide (0.5M) 131 133 1%
High Peroxide (1M) 188 188 0%
The next step was to evaluate how easily these formulations dissolved in water.
We saw that sodium bicarbonate dissolved much slower, and to a lesser degree, than
urea peroxide. Sodium bicarbonate dissolved at 50mg/mL when shaken for 5 minutes.
Urea peroxide dissolved up to 75mg/mL when shaken for 30 seconds. For this reason,
we chose to move forward with urea peroxide. Urea peroxide is used in the remainder
of experiments.
To test the efficacy and feasibility of performing our assay on paper, we first
measured the urea peroxide response, detecting reconstituted urea peroxide incubated
on paper. 50µL samples of varying peroxide concentrations were pipetted onto a filter
paper circle and allowed to incubate for 20 minutes (as they would in the full assay).
Next, the electrodes were folded over to meet the paper and the resulting current
was detected amperometrically at -0.1V versus silver/silver-chloride. The measured
current increased with increasing urea peroxide concentration, as shown in Figure
5·7a.
As a next proof of concept, we tested the current response due to mixtures of
AKG and pyruvate with urea peroxide on paper, shown in Figure 5·7b. The x-axis
shows increasing pyruvate:AKG ratio, while the y-axis shows the impact on current.
Pyruvate concentration has a more dramatic impact on current signal, due to the
stronger reaction kinetics between pyruvate and peroxide(Long and Halliwell, 2012)
and therefore mixtures with more pyruvate more greatly impact the current. This
shows that the reconstitution and mixing of reaction components occur as expected
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on paper.
Figure 5·7: Amperometric detection of Peroxide (A) and AKG, Pyru-
vate mixtures (B) on cellulose paper at -0.1 V versus silver/silver-
chloride. A). Blue dots represent current measurements from pure per-
oxide solutions. B). Black dots represent current measurements from
mixtures of AKG and Pyruvate, coupled to peroxide, showing the more
pyruvate produces a stronger change in the current signal.
5.3.4 4. Zone of Detection
We validated our SPEs by demonstrating a hydrogen peroxide response curve on
Prussian-Blue-modified electrodes made in-house. The measured current increased
linearly with increasing hydrogen peroxide concentration, shown with circles in Figure
5·8. After establishing this proof of concept, we began to vary the size and ratio of
sizes between the electrodes and repeated this same test to look at the effect on the
dynamic range and slope of the response curve.
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Figure 5·8: Amperometric detection of hydrogen peroxide on in-house
SPEs. Error bars represent the standard deviation over 3 measure-
ments.
Next, we tried increasing the size of just the working electrode. By doing this, we
saw an increase in the magnitude of the current, as well as an increase in the slope
of the response compared to the original case. We also tried increasing the size of all
the electrodes; with this, we saw an increase in the dynamic range of the signal, but
also an increase in the variability associated with the signal, captured by the error
bars representing one standard deviation.
We continued to do this and iterate on more sizes and ratios between electrodes,
but variability continued to be a major problem and industrial level consistency was
never achieved, resulting in SPEs that were neither reproducible nor sensitive enough
to capture meaningful signal differences. To remove the potential error related to
screen printing, we decided to move forward with DropSens Electrodes. Though
these are more expensive than electrodes we produce in house, they are more reliable.
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At scale, there is still a huge potential for cost savings.
5.3.5 Device Functionality, full device
After proof-of-concept studies for the assay reactions on paper (5·7), we performed
the complete assay and amperometric measurements using our device. We calculated
current values by running our assay with spiked plasma samples encompassing a
wide range of ALT concentrations. Figure 5·9 shows the relationship between current
and ALT concentration in patient plasma samples. With increasing ALT, current
decreases linearly.
Figure 5·9: Amperometric detection of ALT-coupled reactions at -0.1
V versus silver/silver-chloride in plasma. Blue shading represents dif-
ferent clinically relevant levels of ALT, moving from grade 0 elevations
(light blue- left) to grade 3 (dark blue- right). Solid line represents the
best fit from linear regression.
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Figure 5·9 also shows the clinically relevant ranges of ALT concentrations in pa-
tients with pathology, represented with blue shading. For example, in the case of
hepatoxicity due to medications, patients with ALT elevations of grade 2 or higher
are generally switched to new medications. Patients with ALT elevations of grade 0
or 1 continue to be monitored regularly to ensure their ALT levels do not rise into the
next zone. Based on the linear fit, we can quantify samples in each of the clinically
relevant zones.
Additionally, Figure 5·9 shows that between ALT concentrations of 25 and 200U/L,
the assay produces current proportional to ALT concentration, as shown in Figure
5·9, encompassing a wide linear range of ALT concentrations with an R2 value of
0.9622. Based on this linear signal, current values can be used as an indicator of
ALT concentrations in solution. The allows us to calculate the sensitivity and limit
of detection (Armbruster and Pry, 2008) for this assay, according to the following
equations:
Analytical Sensitivity =
Slope of the Standard Curve
Area of the Working Electrode
(5.1)
Limit of Detection = Limit of Blank + 1.645(SDlow concentration sample) (5.2)
where the limit of blank is defined as:
Limit of Blank = meanblank + 1.645(SDlow concentration sample) (5.3)
The slope of the standard curve (108 nAmps/(U/L)), was divided by the area of
the DropSens working electrode (diameter=4mm), and the analytical sensitivity was
found, according to equation 3.1, to be 8.5 nA/(U/L * mm2). Additionally, the limit
of detection, according to equation 3.2, to be 81.9 U/L ALT. In the following section,
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we will compare this value against other values published in the literature.
Next, we evaluated our assay performance compared to the gold standard method.
To do this, we used our assay and standard curve to quantify additional plasma
samples and compared them to the gold standard clinical zones. Each of the samples
was tested 3 times, and the average calculated concentration of ALT was used to
make clinical decisions.
A two by two table (5.2), was constructed to quantify how well our assay faired in
clinical decision-making power. Any samples that our assay quantified into the cor-
rect clinical decision were deemed in agreement with the gold standard. Any samples
that our assay quantified into a different clinical decision, were deemed in disagree-
ment with the gold standard. Based on this methodology, 15 samples quantified in
agreement with the gold standard, whereas 5 samples quantified in disagreement.
Table 5.2: Two by Two table showing bin placement accuracy of
plasma samples. We compared this work against the gold standard in
terms of clinical decision making; patients with ALT elevations greater
than or equal to grade 2 generally have their medications discontinued
or switched, whereas patients with ALT elevations less than grade 2
do not (shown in Ch 3, Table 1). Therefore, we quantified samples
into these bins to see if they would lead to correct clinical decisions by
community health workers using this tool.
Gold Standard Gold Standard
≥ Zone 2 < Zone 2
This work ≥ Zone 2 7 2
This work < Zone 2 3 8









true negatives+ false positives
(5.5)
Based on equations 3.4 and 3.5 respectively, the diagnostic sensitivity was calcu-
lated as 70% and the diagnostic specificity was calculated as 80%.
5.4 Discussion
In this chapter, we have demonstrated a novel electrochemical ALT assay and POC
platform which is sensitive (sensitivity 8.5 nA/(U/L*mm2)) over a wide linear range
(25 U/L-200 U/L). Other assays in the literature fail to be translated into integrated
POC devices, as they generally require cold chain storage and are prohibitively ex-
pensive (Cooper et al., 1991; Guadarrama-Fernández et al., 2018; Han et al., 2011; He
and Chen, 1997; Huang et al., 2006; Jamal et al., 2009; la Cour et al., 2016; Paráıso
et al., 2014; Peguin et al., 1989; Song et al., 2007; Thuy et al., 2016; Xuan et al.,
2003). Here, we have developed and demonstrated a platform which does not require
cold chain storage and can be fabricated cheaply (discussed later) and easily (figure
2).
Compared to the other electrochemical ALT assays discussed in ch2, our assay
potentially shows increased analytical sensitivity (up to about 100 fold) (Chang et al.,
2007; He and Chen, 1997; Jamal et al., 2009; Kihara et al., 1984a; Thuy et al.,
2016) and a wider linear range (Mizutani et al., 1998; Paráıso et al., 2014; Upadhyay
et al., 2006), shown in Table 5.3. We even show this increased sensitivity in a more
complicated sample matrix (plasma) than many in the literature; our analytical assay
sensitivity is a full order of magnitude higher than the next most sensitive assay
demonstrated in blood plasma or serum.
Though our assay appears more sensitive than others in the literature, there are
limitations to this comparison. Different electrodes and chemistries were used across
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these studies, as well as different methods for the electrochemical and quantitative
analysis. For example, some assays used cyclic voltammetry while others used am-
perometry. The quantitative methods for analyzing traces varied between studies as
well. Future studies are needed to gauge the head-to-head differences in sensitivity.
Additionally, our assay was shown on a paper and plastic platform, as opposed
to in a lab-based modality as all of the other assays in Table 5.3. Not only have we
shown a more sensitive electrochemical assay, but we have, for the first time in the
literature, shown this assay on a field ready platform. Furthermore, the linear range
of our assay is wide and covers clinically relevant zones of pathology seen in DILI.
The lower limit of detection shown here (81.9 U/L) is too high, and not clinically
relevant in detecting stages of liver disease, as this ALT value is already elevated.
To be clinically relevant, the limit of detection should fall within the physiologically
normal range. Future work should focus on lowering of the LLOD to be below 35 U/L
(the upper limit of normal). This can be done, in part, by lowering the run-to-run
variability, or increasing the precision, an important measure in the calculation of
LLOD.
In terms of diagnostic performance, Table 5.2 showcases our ability to quantify
clinical samples with 70% sensitivity and 80% specificity, an acceptable range for
paper diagnostics (Pollock et al., 2013) and an improvement over the existing standard
of care. Though the samples tested were spiked into plasma (as opposed to clinical
samples), this data shows a promising proof of concept; our device could be used as a
screening tool to aid in clinical decision making in the field. Though the samples do
not quantify perfectly, and optimization is required, the samples oftentimes quantify
into the appropriate clinical grades and therefore lead to correct clinical decisions.
Additionally, we showed the stability of these strips over time. The ALT reaction





































































































































































































































































































































































































































































reaction zone was shown to be stable for 60 days. This shows that over this minimum
time period, the device could be stored free from cold chain and still perform as
expected. As discussed earlier, many technologies fail for this very reason (Cooper
et al., 1991; Guadarrama-Fernández et al., 2018; Han et al., 2011; He and Chen, 1997;
Huang et al., 2006; Jamal et al., 2009; la Cour et al., 2016; Paráıso et al., 2014; Peguin
et al., 1989; Song et al., 2007; Thuy et al., 2016; Xuan et al., 2003).. Therefore, this
is a huge and important win, as our technology can overcome this major barrier.
In the future, stability experiments should be performed over a longer time period
and in more hot and humid conditions to evaluate the long-term stability of the
device.
5.5 Movement towards the World Health Organization’s “AS-
SURED” criteria
This platform technology meets many of the metrics outlined in the ASSURED cri-
teria (Kosack et al., 2017). Among the parameters that are most relevant for this
chapter are “Affordability” and “Equipment free,” discussed in more detail below.
This device is affordable, an important parameter of the ASSURED criteria. The
material cost (paper, plastic, reagents) comes to $0.28, while the commercially avail-
able SPEs cost $4.00 per chip. Though $4.00 per test is too high, this would come
down dramatically when sourced in bulk. For example, glucometer strips come to
about $0.15 per chip. Therefore, we could assume SPEs for our test, when bought
at scale, would be in the ballpark of $0.15. Pricing of this device and the associated
impacts are discussed in more detail in Ch6.
Additionally, the device is equipment free, as only an electrochemical reader (ex.
glucometer) is used. There is no need for a power source and no need for cold storage.
This is huge progress in development as past assays have failed to translate because
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of these two major barriers.
The ASSURED criteria and its limitations are discussed in more depth in chapter
7.
In this chapter, we have demonstrated a fully integrated, novel ALT screening
device. We have shown good sensitivity and specificity in 20 spiked plasma samples.
Specifically, we have shown up to about 100 fold increase in sensitivity in 1) a more
complicated sample matrix (plasma as opposed to buffer) and 2) on a more field
ready platform (paper and plastic device as opposed to lab setup). This increase is
sensitivity is important in ensuring that our test will more correctly identify patients
with DILI, a very important characteristic of a diagnostic tool.
Although our device is well on the way to checking off many attributes of the
ASSURED criteria, field testing is needed to truly assess the feasibility of this device
in the field. Future testing will focus on usability studies with our collaborators
in Burundi. For example, our device requires a couple of steps to be executed at
different time points. Usability studies will help us to assess and hone in on how
easily the current setup and time restrictions are integrated into the existing health
care landscape. From this data and feedback, we will be able to purposefully tweak
aspects of the design, if warranted, to make it more impactful in the field. This is
discussed more in chapter 7.
Overall, this is the first electrochemical ALT device of its kind and has the poten-
tial to be impact patient care in LMICs. In the following chapter, we will look at a
specific use case for this technology.
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Chapter 6
Economic Evaluation of Screening
Interventions for Drug Induced Liver
Injury
6.1 Introduction
In the previous chapter, we validated an electrochemical device for liver function
testing at the point-of-care. This device is the first of it’s kind and represents a huge
step towards improving patient care in low resource settings. Specifically, patients on
HIV and TB medicines. In this chapter, we will discuss a use case for this technology
and analyze the effectiveness and cost-effectiveness associated with it.
The morbidity 1 and mortality burdens of HIV/AIDS and TB continue to be a
significant global challenge, with a disproportionate impact on populations of low-
and middle-income countries (LMICs). Currently, 36.9 million people are living with
HIV/AIDS worldwide; 80% of these people live in LMICs (World Health Organiza-
tion, 2019a). Annually, 1.5 million patients die from TB; 98% of which live in LMICs
(World Health Organization, 2020).
Over the years, billions of dollars have been spent on HIV and TB relief, spear-
headed through programs such as the U.S. President’s Emergency Plan for AIDS Re-
lief and The Global Fund to Fight AIDs, Tuberculosis, and Malaria(Henry J Kaiser
Family Foundation, 2019a; Henry J Kaiser Family Foundation, 2019b). While these
1Sections of this chapter are adapted from (Moed et al., 2020)
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efforts have helped to make significant gains in expanding access to lifesaving HIV
and TB medications, there is a systematic failure to monitor patients on these med-
ications for important side effects, such as drug-induced liver injury (DILI) (Allain
and Opare-Sem, 2016).
Patients on anti-retroviral therapies (ARTs) and anti-TB drugs are at an elevated
risk of liver injury and acute liver failure due to DILI, as both HIV and TB medications
are hepatotoxic. For example, in Ethiopia, 32% of adults on ARTs showed varying
levels of DILI, measured by an increase in biomarker alanine aminotransferase (ALT)
(Wondemagegn et al., 2013). In Uganda, 30% of adults with HIV showed markers of
DILI, also measured by an increase in ALT, due to TB medications (Ocama et al.,
2008).
For detection of hepatocellular injuries, ALT screening techniques can be used
(Lilford et al., 2013). In high-income settings, this is accomplished through moni-
toring of ALT and the other components of the liver panel through a venipuncture
blood draw, followed by centrifugation to separate serum, and then testing of the
serum through an absorbance-based assay on an automated platform in a centralized
laboratory (York, 2017). In LMICs, this testing is near impossible due to a lack
of trained phlebotomists, equipment and reagent shortages (Allain and Opare-Sem,
2016). Additionally, supply chain issues add major delays in clinical decision-making
and a significant loss in patient follow-up (Allain and Opare-Sem, 2016). For these
reasons combined, the gold-standard test is not currently feasible at the point-of-care
(POC) in LMICs.
Currently, several ALT monitoring devices are in development to meet the need
for routine screening of liver function in HIV and TB patients in LMICs (Moed and
Zaman, 2019a; Wang et al., 2016; Pollock et al., 2012; Moser et al., 1997). These
ALT tests have the potential to bring DILI monitoring to settings where it is not
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currently feasible with the gold standard. Despite this progress, there are no clear,
quantitative analyses of the benefits POC testing can bring to this population.
This paper serves to analyze the potential cost-effectiveness of POC methods for
ALT, informing us as to what parameters of the technology are most important to
consider and why. We focus on Burundi as a test case for a resource limited setting
with a high burden of coinfection, as well as one of the highest rates of HBV (World
Health Organization, 2017; Standaert et al., 1989).
In this study, a Markov Model is used to evaluate different methods for DILI
screening in a cohort of HIV and TB coinfected patients. This analysis was informed
with data from our partners on the ground in Burundi at Village Health Works (Vil,
2007).
6.2 Methods
We used a Markov Model (Lee et al., 2019; Rajasingham et al., 2017; Tada et al., 2018;
Tanajewski et al., 2017; Wali et al., 2018; Estes et al., 2018) to evaluate 2 different
interventions for liver function testing in a hypothetical cohort of patients in Burundi.
We compared the impact on health outcomes as well as the cost-effectiveness across
strategies.
6.2.1 Model Structure and Assumptions
A population of 2,223 virally suppressed HIV patients, coinfected with TB, are ini-
tiating a standard 6-month TB therapy. After TB treatment, patients are either
cured (continue to live with HIV, no TB coinfection), not cured (continue to live with
HIV/TB coinfection), or dead.
Patients can develop hepatotoxicity at any point during treatment and will present
with liver enzyme (ALT) elevation at either >3x or >5x the upper limit of normal
(ULN) (Program, 1998). A subset of hepatotoxic patients will develop symptoms;
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only these symptomatic patients will be diagnosed with DILI through clinical mon-
itoring. Clinical monitoring is completely based on symptom development; e.g. if a
patient develops symptoms of hepatoxicity, they will be diagnosed through clinical
monitoring. Patients with asymptomatic ALT elevations go undetected in this base
case, while their livers still endure damage.
Patients diagnosed with hepatoxicity are changed from first line to second line
medications. Second line drugs are reserved for patients that experience toxicities, as
they are less hepatotoxic but more expensive.
We introduce screening interventions where all patients in the population are
screened monthly for ALT, and patients with elevations move through the appropriate
model states, shown in Figure 6·1.
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Figure 6·1: Schematic of Markov Model. a. Macroscopic view of the model popula-
tion. All patients in the cohort are HIV/TB coinfected and are initiating a standard
6-month TB therapy. After TB treatment, patients are either cured (continue to live
with HIV, no TB coinfection), or not cured (continue to live with HIV/TB coinfec-
tion), or dead. b. HIV/TB patients can develop hepatotoxicity at any point during
treatment and will present with ALT elevation at either >3x or >5x the ULN. A sub-
set of hepatotoxic patients will develop symptoms; only these symptomatic patients
will be identified through clinical monitoring and diagnosed with DILI through a gold
standard test. Once diagnosed with DILI, patients move through the above states;
they are switched to second line TB medications and remain monitored (through gold
standard testing) until ALT levels normalize. In subsequent scenarios, we introduce
screening interventions where all patients are screened monthly and patients with ele-
vations identified through screening tests move through the appropriate model states
as shown.
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6.2.2 Simulated Intervention Pathways
At the start of each month, patients are screened for hepatotoxicity using one of two
interventions. If patients present with ALT>3x ULN with symptoms or ALT>5xULN
with or without symptoms (Program, 1998), their medications are stopped and ap-
propriate actions are taken to protect liver function, shown in Figure 6·1. Once ALT
elevation is identified through screening, patients move through the same stages as
patients identified with clinical monitoring. The screening approaches used in this
model are:
6.2.3 Simulated Screening Method 1: Automated gold standard testing
Gold standard testing consists of a blood draw by a trained phlebotomist followed
by the processing of blood samples in a centralized laboratory with an absorbance-
based assay on automated, expensive equipment. Blood must be transported to the
centralized lab before testing, resulting in lag time. Results are hard to communicate
back to the patient as they have already left the clinic (Allain and Opare-Sem, 2016).
6.2.4 Simulated Screening Method 2: Electrochemical paper-based test
This type of test works with a drop of blood from a finger prick, eliminating the need
for a trained phlebotomist. The user-process is fairly streamlined, and results can be
communicated to the patient quickly, as this test is done at the POC. This test could
be thought of as resembling a glucose test (finger prick of blood, onto test strip, into
glucometer, quantitative result). (Moed and Zaman, 2019a)
6.2.5 Parameters
To estimate the cost effectiveness of screening interventions for DILI, we used a
Markov Model with a 1-month cycle. The model run for 6 cycles to simulate a
full 6-month treatment plan. Each patient has a probability of death related to HIV,
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related to TB, or from other causes (i.e. general mortality rate in Burundi). Addi-
tionally, patients who show increased ALT have a probability of dying from DILI.
Transition rates (arrows in Figure 6·1b) were then adjusted to ensure the total num-
ber of people in a state (rectangles in Figure 6·1b) at the simulation’s end matched
the listed cumulative parametric values from literature, depicted in Table 6.1.
Table 6.1: Cumulative rates of mortality, transaminitis, and other
factors related to HIV/TB coinfected patients.
Value Source
Mortality from HIV 2.13% (World Health Organization, 2019b)
Mortality from TB (in HIV positive patients) 12.4% (Institute for Health Metrics and Evaluation, )
Mortality from other causes 1.3% (United Nations Childrens Fund, )
Success rate to standard anti-TB treatment for new cases 87% (World Health Organization, 2005)
Rate of transaminitis with ALT >3x ULN 11.4% (Rajasingham et al., 2017)
Rate of transaminitis with ALT¿5x ULN 4.46% (Rajasingham et al., 2017)
Rate of symptoms of hepatotoxicity in patients with ALT >3x ULN 0.6% (Iso, 2012)
Rate of symptoms of hepatotoxicity in patients with ALT >5x ULN 1% (Iso, 2012)
6.2.6 Cost-effectiveness Analysis
In the base case, asymptomatic patients (ALT >3-5x ULN) go undetected while their
livers are silently damaged. The goal of intervention is to minimize the time spent
by patients in this state and maximize the time they spend receiving appropriate
treatment for toxicities as well as their underlying disease. Therefore, intervention
efficacy is calculated as a ratio of patients who receive proper treatment for liver
toxicities compared to the total group of patients experiencing toxicities.
For each intervention, costs were calculated based on pricing from our clinical
collaborators at Village Health Works (Vil, 2007) in rural Burundi, shown in Table
6.2. We calculated incremental cost-effectiveness ratios (ICERs) for each strategy by
dividing the additional cost by the additional efficacy gained compared to the next
most expensive strategy.
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Table 6.2: Costs of healthcare related to HIV and TB patients from
Village Health Works (Vil, 2007) in Burundi.
Cost (US Dollars)
HIV Associated Costs
Monthly Cost of ART 6.31
Monthly transportation cost on ART 5.49)
Monthly cost of lab tests 1.81)
Monthly consultation costs 1.18
TB Associated Costs
Monthly cost of first line TB 5.00
Monthly cost of second line TB 21.75)
DILI Associated Costs
Gold-standard automated ALT test 2.40
Quantitative paper-based ALT test 1.20
1 week hospitalization for DILI 6.40
6.2.7 Sensitivity Analysis
We then performed a robust sensitivity analysis, varying the rates and costs of pa-
rameters pertaining to liver injury and TB treatment, and assessed the impact on
ICERs. Deterministic and probabilistic sensitivity analysis were performed, as per
other methods (Chaillon et al., 2019; Filipovi’c-Pierucci et al., ; Lee et al., 2019;
Morgan et al., 2017; Nagai et al., 2020; Rajasingham et al., 2017; Tanajewski et al.,
2017; Wali et al., 2018).
For deterministic analysis, each parameter was modulated between the upper
and lower bounds of the plausible range, shown in Table 6.3. Where necessary, the
plausible range was determined by alternative values found in literature. The cost
analysis was repeated in the same way described above for each parameter throughout
the sweep, quantifying the impact on the cost effectiveness through updated ICERs.
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This analysis helped to identify key drivers of the results.
Table 6.3: Plausible range of parameters used in deterministic sensi-
tivity analysis.
Initial Value Plausable Range
TB Associated Paramters
Month cost of first line TB $5.00 $2.00-$10.00
Month cost of second line TB $11.24 $5.00-$25.00
DILI Associated Paramters
Mortality from Hepatotoxicity 5.2% 2-8%
Rate of symptoms of hepatotoxicity in patients with ALT >3x ULN 0.6% 0-1%
Rate of symptoms of hepatotoxicity in patients with ALT >5x ULN 1% 0-3%
Cost of Quantitative paper-based ALT test $1.20 $0.80-$3.00
Paper Test False Positive Rate 25% 5-30%
Paper Test False Negative Rate 10% 5-30%
Population Associated Parameters
Number of patients 2223 50-3000
We also performed a probabilistic sensitivity analysis (PSA) around uncertainty
related to the paper test. Beta distributions (Chaillon et al., 2019; Rajasingham
et al., 2017; Tanajewski et al., 2017) were used to select for the false positive and
false negative rates of the paper-based test, and a log normal ((Chaillon et al., 2019;
Tanajewski et al., 2017) distribution was used to approximate the cost of test. 350
sets of 10 iterations each were performed through a Monte Carlo simulation, where
each iteration selected new parameter values for the false positive, false negative,
and cost, according to the previously defined density function of the test (Filipovi’c-
Pierucci et al., ). Cost-effectiveness acceptability curves were constructed, showing
the probability that the paper-based test is cost-effective as a function of a policy
makers ceiling Willingness to Pay threshold, or ICER. This metric is a moving esti-
mate of what policy makers might be willing to pay per health benefit. This will vary
by healthcare setting, so in the analysis we consider a wide range.
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6.3 Results
6.3.1 Cost Effectiveness Analysis
With clinical monitoring alone, there was a 32% success rate of capturing patients
who silently suffer from DILI, or 32% efficacy at a total cost of $264,388.72. Both
DILI screening interventions resulted in greater efficacy at a higher cost, shown in
Table 6.4. Using the quantitative paper test resulted in an additional 56% efficacy for
an additional $30,900.11, or $549.82 per additional percent efficacy. Using the gold
standard method, there was an additional 5% efficacy over the quantitative test, for
$1,430.97 per additional efficacy percentage.
Table 6.4: Cost effectiveness analysis for DILI monitoring strategies.
Total Cost ($) Incremental Cost ($) Efficacy (%) Incremental Efficacy ($) ICER ($/%)
Clinical Monitoring $264,388.72 - 32 - -
Quantitative Paper Test $295,288.83 $30,900.11 88 56 549.82
Gold Standard Test $302,787.10 $7,498.28 93 5 1.430.97
6.3.2 Deterministic Sensitivity Analysis
The deterministic sensitivity analysis showed the parameters with the most influence
on the ICER, for the paper test compared with clinical monitoring alone. Bigger bars
represented a bigger impact on the cost analysis, as shown in Figure 6·2, while the
vertical black line represented the baseline ICER of $549.82. Bars that spread wide
to the right of the black line represented parameters that increase the overall ICER
of paper testing compared with clinical monitoring. Bars that spread wide to the left
of the black line represented parameters that decreased the overall ICER of paper
testing compared with clinical monitoring. Small bars represented parameters that
do not have much impact on the ICER.
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Figure 6·2: a) Tornado Table. ICER value for each parameter as it is
swept through the ranges shown in Table 6.3. The black line represents
the baseline ICER, shown in Table 6.4, for paper testing compared with
clinical monitoring, $549.82. Parameters marked with an * represents
a sweep where the gold standard method became dominating (more
cost effective than the Paper Test). b) Paper Test ICER compared
with Gold Standard ICER, as a function of the Cost of Paper Test.
The paper test ICER is compared with baseline clinical monitoring,
whereas the gold standard ICER is compared with paper testing.
Shown in Figure 6·2a, the top three parameters which impact the cost analysis
were the 1. number of patients in the population, the 2. cost of paper test, and the 3.
rate at which patients became symptomatic with ALT>5x. These three parameters
are discussed in depth below.
The number of patients in the population has the greatest impact on the cost-
effectiveness analysis, as shown in Figure 6·2a. As the population became smaller,
the total intervention cost became cheaper as less tests were needed to screen the
population in its entirety. Despite this, at any population size, paper testing always
showed a large increase in efficacy over clinical monitoring alone.
The cost of the paper test is also very important when making cost analysis
conclusions. As the cost of the paper test increased, the ICER increased as well.
At a cost of $1.60 per test, the gold standard method became more cost-effective,
dominating over the paper test: offering more efficacy for a lower ICER. This was
represented in Figure 6·2a with an asterisk and is shown in more detail in Figure 6·2b.
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As the cost of the paper test increases, the paper test ICER steadily increases as well
while the gold standard ICER steadily decreases. At a critical value of $1.60, the
ICER for gold standard testing becomes less than the ICER for paper testing (shown
in Figure 6·2b), indicating that the gold standard test has become more cost effective.
This critical point is important to keep in mind while designing and validating a paper
screening test.
Shown in Figure 6·2a, with increasing rates of symptomatic patients with ALT<5x,
the efficacy of clinical monitoring increased as well, as patients that were symptomatic
were caught and monitored with clinical monitoring alone. This increased the ICER
of the paper test as the jump in efficacy decreased. Though different medications
may result in different rates of DILI, medications with higher hepatotoxicity rates
are less likely to be used in the clinic. Therefore, this increased ICER with increased
hepatotoxicity is not of grave concern, as it is unlikely to occur in practice.
6.3.3 Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis showed which POC method was the most cost-
effective at a range of Willingness to Pay thresholds, capturing the uncertainty related
to the paper test parameters by selecting false positive, false negative, and test cost
rates for every run. To ensure the results from any run were not due to inherent
randomness in the modeling framework, the results of each set of parameter selections
were averaged over 10 repeats. Throughout this analysis, paper screening tests always
resulted in better treatment of patients experiencing DILI, shown with a gray line in
Figure 6·3. The gold standard method is not included in this comparison of POC
methods, as gold standard testing is not feasible at this time at the POC (Allain and
Opare-Sem, 2016). For a probabilistic analysis including gold standard, see Figure
S1.
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Figure 6·3: Willingness to Pay Threshold.
As shown in Figure 6·3, the most cost-effective option for screening under a Will-
ingness to Pay Threshold of about $570 was clinical monitoring. Though clinical
monitoring showed only a 32% success rate (Table 6.4), it was the only option when
other screening tests are above the ceiling Willingness to Pay. Above a Willingness
to Pay Threshold of about $570, the paper test was the most cost-effective method
to improve patient outcomes the majority of the time.
6.4 Discussion
Due to logistical challenges, gold standard DILI screening fails to be executed at the
POC in LMICs. For this reason, we used cost-effectiveness analysis to gauge the
efficacy of a paper-test that could be implemented in these settings.
Screening for ALT at the POC allows for earlier detection of DILI, preventing
premature death. The paper test modeled here offers a great benefit over clinical
monitoring alone, at much less of a cost than gold standard testing. Because of
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this, decision makers can feel confident that when automated ALT monitoring is not
practical, paper testing still provides a significant benefit. As shown, using ALT
screening tests improve outcomes by more than 50% over clinical screening alone.
Therefore, policy makers can feel confident that when gold-standard testing is not
available, paper testing can provide large value.
The deterministic sensitivity analysis shows that the model is robust to most of
the input parameters, with the cost of the paper test being the most important in
cost analysis decisions. When the cost of the paper test is below $1.60 per test, the
paper test is more cost-effective than gold standard testing. For reference, a single
glucometer test typically costs about $0.30 (Ahn, ). Therefore, the $1.60 metric
for this type of POC test is within a realistic ballpark. Other test characteristics
such as false positive and negative rates have less of an impact on the cost analysis.
Therefore, when developing and optimizing tests for the field, cost of the test is the
greatest consideration.
DILI levels in different regions and countries across Africa can fluctuate due to the
probability of other coinfections. As shown through deterministic sensitivity analysis,
the cost-effectiveness is not dependent on DILI rates and symptoms, demonstrating
that this model is robust to geographical region. That being said, this model should
still be tailored to a specific region before health and policy decisions are made.
As shown in the PSA, below a value of about $570 per incremental efficacy, clin-
ical monitoring is most cost-effective. This is because the paper test cannot be im-
plemented below this cost. Above this threshold, the paper test dominates, showing
that it is more cost-effective over clinical monitoring the majority of the time.
To improve this model further, more complexities could be added to the model
population, including underlying hepatitis, namely Hepatitis B Virus (HBV) and Hep-
atitis C Virus (HCV). These conditions increase risk of DILI in HIV/TB coinfected
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patients (World Health Organization, 2017) and would therefore could affect transi-
tion probabilities between states. According to the World Hepatitis report, 7.4% of
HIV patients have underlying HBV and 6.3% have underlying HCV (World Health
Organization, 2017). To make the model more specific to these underlying conditions,
rates of toxicities would need to be studied specifically in these populations.
Another limitation of this study is the use of incremental efficacy as a percent-
age, as opposed to incremental efficacy in Quality Adjusted Life Years (QALYs).
Because percent efficacy is used, the results are not as easily comparable between
this study and others, which generally use QALYs. QALYs, though often used in
cost-effectiveness analysis, remain controversial (Benson, 2017; Brower, 2008; White-
head and Ali, 2010) and are not used as a measure of efficacy in this study, as this
metric does not appropriately represent the health disparities of liver toxicities. Us-
ing QALYs, patients with and without asymptomatic toxicities are weighted at the
same level because asymptomatic diseases do not impact the patient’s quality of life.
Therefore, as patients in the problem state (elevated ALT) are often asymptomatic,
the QALY utility weighting does not capture their ill health. As we’ve shown, using
an ALT screening method to test for toxicities greatly improves patient outcomes in
the DILI population and helps an additional 50% of these patients get the help they
need.
Despite these limitations, the modeling and sensitivity analyses shown here illus-
trate that paper-based screening for DILI is an effective, cost-conscious method of
improving patient outcomes. Additionally, the framework provided in this paper can
help scientists and engineers avoid failure in technology development by identifying
the important parameters that technology must meet and allowing creators to design
to those specs. Here, we found the cost per test was the most important param-
eter, but when adapting this framework for other technologies, different important
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parameters may emerge.
When gold-standard testing is not broadly implementable, policy makers can feel
confident that paper-based testing adds significant benefit. Scientists and engineers
should also keep these analyses in mind, trying to limit the cost of an ALT screening




The work presented in this thesis set out to fill the current and critical void in diagnosis
and management of liver diseases in patients with HIV/AIDS and TB in low- and
middle-income countries (LMICs). Throughout the body of this work, we set forth
a novel, electrochemical device to quantify liver biomarker, alanine aminotransferase
(ALT), concentrations from whole blood samples at the point-of-care (POC).
Specifically, we:
• developed and validated a novel, electrochemical assay to quantify ALT
• integrated the novel assay into a portable platform, usable at the point-of-care
and
• computationally demonstrated the effectiveness of portable platform in low-
resource healthcare settings
7.1 Innovation and Impact
We developed a novel, electrochemical assay to quantify ALT from whole blood with
high sensitivity, over a wide range of pathology. Our assay is distinctly different from
other assays reported in the literature, as we do not use a glucose oxidase or pyruvate
oxidase as a couple mechanism. Instead, we couple ALT production of pyruvate to
a non-enzymatic hydrogen peroxide reaction. This results in electrodes which are
affordable and do not require cold chain storage.
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In collaboration with Dr. Fredric Gordon at Lahey Medical Center, we validated
this assay in patient plasma samples. Our assay shows analytic sensitivity two orders
of magnitude greater than the next comparable assay in literature. When using this
assay with patient samples, we showed high diagnostic sensitivity (S from ASSURED)
and specificity (S from ASSURED) in terms of clinical decision making. In 23 out of 24
samples, quantification of ALT resulted in the correct medical decision, demonstrating
the robustness (R from ASSURED) of our assay.
We then developed a paper-and-plastic point-of-care device to precisely quantify
ALT concentrations from whole blood. We showed that this integrated device could
successfully extract plasma from whole blood, eliminating the need for a centrifuge at
the POC. This was a huge step toward making sure this technology was POC com-
patible (E (equipment free) from the ASSURED criteria). In collaboration with Dr.
Fredric Gordon at Lahey Medical Center, we validated our device with patient plasma
samples. Through the creation of this device, we worked with partners on the ground
in Burundi and Thailand to make sure that our device was user-friendly (U from
ASSURED) and easily integrate-able within the existing healthcare infrastructure.
We used a Markov Model to explore the impact of our technology at the point-of-
care in low-resource healthcare settings. We looked at a hypothetical cohort of HIV
and TB coinfected patients in rural Burundi and introduced liver function screening
to their treatment plan. We assessed the impacts on quality-of-life and medical costs
to the health-care system. We showed that point-of-care testing for liver function
in this patient population is cost-effective (A from ASSURED) and could greatly
improve patient outcomes.
Figure A·1 summarizes which aspects of the ASSURED criteria have and have
not been met through the work set forth in this thesis.
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Figure 7·1: Graphic depicting which of the ASSURED criteria have
been met through the work put forward in this thesis.
Here, It is important to mention that the ASSURED criteria comes with its own
limitations, as these criteria are generic and must be adapted to fit to each diagnostic
need. Not all tests methods can be simplified to fit within ASSURED. First example,
both laboratory infrastructure and equipment are required for diagnosis with medical
imaging. ASSURED is geared towards disposable diagnostics and ignores the high
value hardware that is sometimes very necessary for diagnosis (such as CT, X-ray,
MRI). Additionally, it makes no mention of the need for human resources that are
needed for contained use of technologies in low resource settings. This is an important
consideration when looking to implement a sustainable test to be used long after the
researcher has left.
Though the ASSURED criteria isn’t perfect, it represents a good benchmark for
disposable diagnostics. Therefore, we used it as the framework for development of
our ALT test.
This innovative method for quantifying ALT is meant to serve as a screening and
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triage tool for healthcare workers in low resource settings. Usually, these healthcare
workers make their decisions based on symptoms alone. This assay will provide them
with an additional piece of quantitative data to aid in their clinical decision making.
If a patient does test high for ALT using this device, they will then be tested with
the gold standard to verify diagnosis before a treatment decision is made.
The data shown throughout this work demonstrates the efficacy of this screening
device, adding a relevant quantitative metric to the healthcare workers repertoire and
narrowing down the selection of patients who require gold standard testing.
The potential impact of this technology is huge, as all patients on HIV and TB
medicines in low-resource settings could benefit from regular DILI screening. Cur-
rently, 20 million people live with HIV/AIDs in LMICs; additionally, in 2019, TB
claimed 1.47 million lives in these same regions. The technology developed here has
the potential to fill the current void in diagnosis of liver damage and to connect
millions of people to treatment.
7.2 Limitations
In this thesis, preliminary experiments with patient samples showed great diagnostic
sensitivity and specificity. The novel assay was able to provide quantitative informa-
tion and aid in clinical decision making. That being said, additional patient samples
are needed. Testing should be done with a wide array of whole blood, including both
physiologic and pathologic samples. ALT elevations spanning all grades should be
tested and, pending results, further optimization of the device may be required.
Additionally, all of the data included in this thesis was collected in a lab setting
where the environment is fairly well controlled. Future studies should include testing
in a field setting where environmental conditions are always changing.
Though the work set forward in this thesis seems promising, there are still many
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factors inhibiting translation into the field (delivery to end-users (D from ASSURED)).
These factors, and some initiatives to overcome them, are discussed in detail in the
following sections.
7.3 Barriers and bottlenecks in the field
As a whole,1 there is a lot of academic movement towards innovative and sensitive
assays for the detection of ALT, but the majority of this effort is focused on assay
development as opposed to making these assays field deployable in LMICs. Many of
the assays discussed above date back to the 1950s and 60s, yet there has been no
development of devices based on the assays in those publications. Even the Pollock
device, which underwent field testing and showed promising results, failed to make
it past pilot testing. Therefore, in spite of this academic movement, we see little
translation into the field.
7.3.1 Why the lack of development into integrated technologies?
For successful translation of technology out of the lab and into the field, it is important
to show integration of an assay into a single platform capable of sample collection
and preparation, analyte-specific chemistry, signal production and detection, and
reporting of a result. This makes for a streamlined process, with minimal burden on
the end user. For the purposes of academic publication, integration takes a backseat to
assay development, as integration of existing technologies is not financially rewarded
in the way that new chemistries and novel assays are.
7.3.2 Why do the (very few) integrated technologies fail?
First and foremost, this can be attributed to a weak healthcare system. This is a
systemic problem with a huge scope and therefore does not have a singular, simple
1Sections of this chapter are adapted from (Moed and Zaman, 2019b)
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solution. In the following paragraphs we will discuss smaller and more acutely tar-
getable problems. Firstly, oftentimes clinical trials in LMICs are developed solely
for the benefit of the high-resource country running the trial. This results in physi-
cians from low-resource settings acting as data collectors for trials designed elsewhere
(Harding, 2016).
Additionally, funding proves to be a major problem as there is a lack of clear,
feasible funding pathways for bringing products to the market. Typical grants from
the National Institutes of Health (NIH), National Science Foundation (NSF), and
other philanthropic organizations focus more on technology innovation, rather than
clinical testing of technologies previously developed. Additionally, these governmental
organizations focus more on innovation for use in the United States (J Bull et al.,
2012). Specifically for global health, the funding pool remains very small relative to
what high-income countries spend on their own health, representing only 1% of high-
income health expenditure (Dieleman et al., 2014). Also, funding priorities (both
governmental and foundation-based) often change with public health trends. This
generates insecurity in long-term funding for specific public health challenges, creating
a difficult environment to make any true impact. For example, currently global public
health policies and funding agencies are concentrated on health conditions due to
infectious diseases(Ollila, 2005). This means that funding opportunities for other
areas of health are much less lucrative and much less stable.
Aside from the funding landscape, there are many other pronounced barriers to
implementation. Firstly, inventors from high-resource settings often find it challeng-
ing to determine whether to seek regulatory approval in their own country, which
could potentially lead to design changes, and increases in cost and time to implemen-
tation(Chao et al., 2014). This is compounded by the challenge of attracting investors
to low-margin medical devices for global health. Traditional (i.e. financial) return on
104
investment is often low or even negative in global health; therefore, it is difficult to
make a business case for going to market. In addition, to secure global intellectual
property (IP) protection, patent applications need to be filed in each country where
the device will be used. A lack of IP protections in many LMICs further discourages
investment in this area (Chao et al., 2014).
Lastly, many technologies are developed in the academic space by technically
strong-minded individuals, but these same individuals often have no experience in
commercialization and other business aspects of medical devices. Therefore, it is
nearly impossible for them to scale up the device alone (Chao et al., 2014). Com-
pounding this, it is often hard for this strong academic to partner with industry—
this intensifies the already prominent discontinuity between the discovery stage of
technology development (often in academia) and the trial/eventual marketing stage
(often in industry) (Lutchen, K.R., 2018). This incoherence results from a cultural
divide between the sectors, based on a difference in core values: advancing knowledge
and scientific training (in academia) versus margins and profits, or the bottom line
(in industry).
For all of these reasons, there is a great need for appropriate funding and effective
incentives towards prompt diagnosis of liver disease, specifically in low- and middle-
income countries.
7.3.3 How can we better incentivize and fund development of global
health diagnostics for liver function?
In the very recent past, academics and industry professionals have begun to bridge
the polarizing divide between them and enter into mutually beneficial relationships
(Lutchen, K.R., 2018). This continued partnership could be key to bridging the gap
between the discovery and marketing stages of technology development, therefore
helping to propel technologies from the academic space into the field. Creative incen-
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tives could help to further bridge this gap; incentives of this type exist in the vaccine
and pharmaceutical industries and could be applied here as well.
Looking at recent research from the neglected field of vaccine development, two
promising incentivization campaigns stand out: 1) the Advanced Market Commit-
ment (AMC) model and 2) the Call Options for Vaccines (COV) method. These
models aim to make vaccine sales more profitable and development costs less burden-
some.
In the first model, for a qualifying vaccine, the AMC guarantees a certain price for
a specified number of units. This is subsidized by the sponsors of the AMC, usually
philanthropic agencies and NGO’s, who pay the difference between market value and
the guaranteed price (Brogan and Mossialos, 2013). This incentivizes development
of novel vaccines by guaranteeing a profitable market, post development. To get to
that guaranteed profitable market though, companies must still pay out lofty develop-
ment dollars throughout the scientific process. These development dollars still pose
as a barrier to novel vaccine development, despite the guaranteed AMC market—
therefore, the COV method was developed to help bypass this barrier. With the
COV model, purchasers make payments during the early stages of development in
exchange for reduced future prices (Brogan and Mossialos, 2006). This provides the
developing company an early incentive to continue development, as dollars come in
specified for the task (Brogan and Mossialos, 2006).
In the pharmaceutical space, the Options Market for Antibiotics (OMA) model
combines the principals of both the AMC and COV models (Brogan and Mossialos,
2013; Renwick and Mossialos, 2018). This model aims to incentivize antibiotic de-
velopment for applications in global health, where returns will be low. Here, a third
party, typically an NGO or government agency, will purchase ‘options’ for an antibi-
otic, that they could redeem if/when the drug goes to market (Brogan and Mossialos,
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2013). If they purchase the options early in development, the price would be low,
but the risk of the drug failing would be comparatively high. If they purchase the
options near the end of development, the price would be much higher but the risk of
failure lower (Brogan and Mossialos, 2013). With this model, the purchaser benefits
by incentivizing development of a drug they desire and by receiving the drug at a
discounted price compared to the market cost at the time of launch (Brogan and
Mossialos, 2013). Additionally, the development company benefits from development
dollars, early on and a guaranteed market, post launch.
These methods, though examples of incentives outside of the diagnostic space,
should still pose as valuable models to help rally appropriate funding and execute on
development of diagnostics for the POC. With better incentives and funding, we can
bypass many obstacles to technology development in LMICs.
7.4 Future Work
Future work of this thesis should be aimed at making this technology delivered, or
accessible to end users (D from ASSURED). A major factor in this is testing both
the efficacy and the usability of this novel, electrochemical device in a field setting.
7.4.1 Testing Efficacy
A field trial, or a trial outside of the clinical setting with no implication on patient
trajectory, should be conducted to formally compare our device against the gold
standard. We will use the data gathered to refine the technology and evaluate the
accuracy, precision, and robustness. We will acquire the necessary Institutional Re-
view Board (IRB) approvals in order to ethically test with patient samples and train
all users accordingly. Tests with our prototype will be conducted in parallel to the
usual testing that occurs with patient blood in MMH labs. By using the device with
patient samples from the field, we will gather data as to accuracy, robustness and
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repeatability. The data that we collect will allow us to generate tools such as Risk
Analyses and Failure Modes and Effects Analysis (FMEA).
7.4.2 Testing Usability
Usability will be assessed through a Product Acceptability Test (PAT), using struc-
tured observation and a survey of participants perception on use. This usability
testing is needed to truly assess the feasibility of this device in the field.
Participants would be consented using an informed consent form distributed earlier
as part of an ethics application package. Consenting participants would receive an
instruction manual (or training) for use of the instrument at least a day before. Target
population are clinicians, nurses, laboratory staff, and community health workers who
use the traditional test instrument, which would be the control in this study. Outcome
measure is ease of use of the innovation. Ease of use would be assessed on a 5-point
scale ranging from “easy” to “difficult”. Participants would receive a token gift card
on completing the PAT; as well as acknowledgement in any publication.
7.4.3 A platform technology: extending this work to other liver biomark-
ers
To make this technology more broadly applicable, we can consider assays for other
common liver biomarkers. Typically, liver health is evaluated through a liver function
panel, measuring blood levels of total protein, albumin, bilirubin, and liver enzymes.
Elevations in serum aminotransferases (both ALT and aspartate aminotransferase
(AST)), two enzymatic biomarkers of liver injury, are the most common abnormality
seen on liver function panels19 and enter the bloodstream due to hepatocellular injury
or death. Both transaminases are involved in the breakdown of amino acids.
As we have discussed throughout, ALT catalyzes the transfer of an amino group
from alanine to alpha-ketoglutarate, forming pyruvate and glutamate. AST, on
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the other hand, catalyzes the transfer of an amino group from aspartate to alpha-
ketoglutarate, forming oxaloacetate.
A ratio between concentrations of AST and ALT, called the AST:ALT ratio, can
be used to sort through root causes of liver disease20. For example, an AST:ALT
ratio greater than 2 is indicative of alcoholic liver disease. For cases of acute viral
hepatitis, the AST:ALT ratio is usually less than 120.
Using the ALT technology discussed in this thesis, we can create a similar test for
quantifying AST levels from finger prick samples. Our assay (ch 3) is easily trans-
latable, as alpha-ketoglutarate and oxaloacetate also react with hydrogen peroxide.
Therefore, AST testing can be implemented on a similar platform as shown here.
With both ALT and AST levels together, clinicians can use this technology more
widely, using the AST:ALT ratio to diagnose different types of liver abnormalities.
This technology could be useful in obstetric care to monitor patients and detect
when liver function deteriorates significantly. For instance, in HELLP syndrome.
HELLP, or hemolysis, elevated liver enzymes, and low platelet count, is a progressive
state of preeclampsia that usually occurs before the 37th week of pregnancy. This
device could be used to monitor preeclampsic patients and detect disease progression
early (to HELLP syndrome), so that pregnancy complications can be mitigated.
7.5 Concluding Remarks
There is an urgent need for technologies that enable prompt diagnosis of liver disease
at the POC, specifically in LMICs. This thesis aims to fill this void through the
development of an integrated POC platform for liver function testing. Through the
work presented here, we have validated a novel device that can be used to simplify the
diagnosis and management of liver diseases in low-resource settings, so that patients
all over the world have access to life-saving medical care.
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Appendix A
Quantitative assay for ciprofloxacin and
enrofloxacin formulations
A.1 Introduction
Ciprofloxacin (cipro), 1 a broad-spectrum antibiotic from the fluoroquinolone class, is
used to treat a wide range of infections caused by susceptible bacteria (ex. respiratory,
urinary tract, intestinal illness) (Conley et al., 2018; Sharma et al., 2017). It is one
of the most widely used antibiotics in the world, in both animals and humans, due
to its efficacy, safety, and relatively low cost (Conley et al., 2018). However, evidence
suggests that the widespread availability and use of substandard cipro has increased
the risk of antimicrobial resistance (AMR),(Andersson and Hughes, 2014; Weinstein
and Zaman, 2018) disproportionately affecting developing countries with less stringent
pharmaceutical regulation (Bowen et al., 2015; Cahana et al., 1995; Corti et al., 1995;
De Lappe et al., 2015; Jabeen et al., 2015; Kim et al., 2015; Sharma et al., 2017).
The World Health Organization estimates that up to 10% of medications worldwide
are counterfeit (passed off as real without being evaluated for quality, safety, and
efficacy) or substandard (poor-quality). Of these medicines, 50% are estimated to be
antimicrobial agents of which 78% stem from Asia and Africa (Prazuck et al., 2002).
Specifically, in the case of cipro, many studies have exposed startling rates of
1Sections of this chapter are adapted from (Moed, S. and Hall, M. and Lee, N. and Prazeres da
Costa, C. and Rødland, E.R. and Irani Shemirani, A. and Clifford, K. and Desai, D. and Zaman,
M.H., 2019)
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substandard formulations. For example in 2002, Prazuck et al collected three generic
oral formulations of cipro manufactured in India and upon quality testing, found that
two out of the three formulations varied in ciprofloxacin content by more than 20%
(Prazuck et al., 2002). In 2005, Weir et al collected cipro eye drops sold in India
and found that 20% of samples contained concentrations below the recommended
range (Weir et al., 2005). Additionally, in 2009, Bate et al showed that 10% of cipro
treatments collected in Delhi, India failed at least one of two quality tests (Bate
et al., 2009). This widespread distribution of poor quality cipro, and the linkage to
resistant bacteria, is in part due to a lack of regulatory policies governing appropriate
manufacturing and quality assurance (Sharma et al., 2017).
Many methods are used to assess the quality of cipro formulations, including
the ‘gold-standard’ high performance liquid chromatography (HPLC) and the ‘field-
standard’ thin-layer chromatography (TLC) (Bate et al., 2009; Prazuck et al., 2002;
Weir et al., 2005). Currently, HPLC is the main analysis method for pharmaceutical
formulations but is prohibitively expensive for applications in low-resource settings,
costing upwards of $100,000 with reoccurring annual costs of approximately $20,000
(Scientific, ; Nikolin et al., 2004). Additionally, HPLC requires a centralized lab-
oratory containing the instrument, as well as trained technicians to run it. These
demands cause logistical problems in low-resource settings and are almost never met.
To overcome the barriers of expensive, centralized testing, TLC is used for analy-
sis of pharmaceutical formulations in the field, specifically through a platform called
Minilab. Minilab, comprised of two 45-kilo suitcases containing all necessary test-
ing reagents, is used specifically for applications in resource-limited settings and is
recommended by the WHO for detection of substandard drugs in these areas. But
because of the nature of TLC, Minilab can only be used to determine substandard
drugs qualitatively. This leaves a gap in our ability to assess quality of cipro in a
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precise, quantitative, field-ready manner.
In an attempt to bridge this gap, other groups have worked to develop assays for
cipro quality, using various spectroscopy techniques such as absorbance and fluores-
cence (Cazedey et al., 2013; Durmus et al., 2005; Sastry et al., 1995; Scherer et al.,
2014). Many of these assays utilize toxic or corrosive chemicals and require an ex-
pensive spectrophotometer in a centralized lab with trained personnel and multiple
sample preparation steps. So even though these assays are lower cost than traditional
HPLC, they still incur these barriers in translation to the field.
To fill this gap, we have developed a low-cost assay to determine quality of cipro
in tablets. Substandard formulations have been suggested to be one of the major
forces driving AMR to cipro and therefore, quantitative, portable tests are necessary
for screening (Andersson and Hughes, 2014). We modified our assay to also test for
quality of enrofloxacin (enro), a fluoroquinolone similar in structure to cipro which
is used extensively in veterinary medicine. In animals, enro is metabolized to its
active metabolite, cipro, and is therefore a driver of human-relevant cipro resistance
(Martinez et al., 2006). In this study, we evaluate this novel assay and compare to the
gold standard, HPLC. These assays can be adapted to microfluidic platforms capable
of quantifying fluorescence in a robust, automated, and portable system for medicine
quality testing (Desai and Zaman, 2015; Ho et al., 2015) .
A.2 Materials and Methods
A.2.1 Assay Design
In weakly acidic media, metal ions and surfactant quench the autofluorescence of
cipro antibiotics, via a mechanism described elsewhere (Wang et al., 2014). As shown
be Wang et al., palladium(II) (metal ion) and sodium dodecyl benzene sulfonate
(surfactant) quench the autofluorescence of fluoroquinolones by formation of a ternary
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complex. Based on this, the authors established an assay to quantify palladium(II)
in solution.
In the assay described here, cipro is dissolved in deionized water and mixed with a
‘probe’ solution containing the quenching agents— in our case, palladium(II) (metal
ion) and methyl cellulose (surfactant). A detailed list of components in both the
tablet and probe solutions is shown in A.1. After addition of the probe solution, a
decrease in the autofluorescent signal of cipro is monitored. The cipro/probe solution
mixture is used for quantification to ensure that signal is specific to cipro. If cipro
autofluorescence was used to quantify alone, other molecules in the tablet might
fluoresce similarly, contributing to an unspecific signal.
Table A.1: List of components in tablet and probe solutions. Tablet
and probe solutions, as composed here, were mixed at a 1:1 ratio. Aut-
ofluorescent quenching of cipro was monitored immediately following
mixture.
Tablet Solution Cipro Solution
cipro tablet palladium(II) chloride
water methyl cellulose
acetate buffer pH 4
water
Cipro exhibits a linear fluorescence response in a range from 0.00125 mg/mL to
0.005mg/mL both before and after mixture with probe. This linear trend can be
exploited to quantify samples with unknown amounts of cipro.
A.2.2 Cipro Assay Procedure: Powder
Cipro powder (Fisher Scientific) was dissolved in deionized water at 10 mg/mL (stan-
dard solution) and diluted to 0,005 mg/mL, 0,0025mg/mL and 0,00125 mg/mL. Aut-
ofluorescence of pure cipro powder (excitation 275, emission 450) was detected on
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the spectrophotometer (Molecular Devices SpectraMax M5 Microplate Reader). The
assay was then performed by mixing probe solution, containing methyl cellulose, pal-
ladium chloride and acetate buffer at pH 5, with the cipro solutions at a 1:1 volume
ratio. Autofluorescence was detected again on the spectrophotometer for 10 minutes,
every 10 seconds. These experiments were conducted in a 96-well plate system.
A.2.3 Cipro Assay Procedure: Tablet
Cipro tablets (500mg) were dissolved in 50 mL of deionized water and filtered through
a 0,22 um cellulose acetate syringe filter (Abulo). The cipro solution was then diluted
to the same concentrations explained above and the procedure for powder was followed
exactly.
A.2.4 Cipro Quantification
Samples of unknown concentration were compared to samples of known concentra-
tion via a linear fluorescence signal. The linear region (0,00125 to 0,005 mg/mL) of
fluorescence from the powder samples was used to construct a line, and the tablet
solutions were quantified using this line. Three tablet brands were tested: Brand A,
Brand B, and Brand C. A scaling factor (ratio between the slope of powder and tablet
standard curves) was used to scale the tablet samples to the powder samples, so that
the powder line of best fit could be used for quantification.
A.2.5 HPLC Protocol
HPLC was used as a gold-standard comparison to help assess the accuracy of our
novel assay. A solution of 0,025M phosphoric acid (Fisher Scientific) was adjusted
to pH 3,0 with triethylamine (Fisher Scientific). For the mobile phase, acetonitrile
and the phosphoric acid solution were mixed 13:87 (United States Pharmacopea,
2015). Cipro standard solutions were prepared in water at 5 concentrations between
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0,005mg/mL and 0,1 mg/mL.
HPLC (Agilent 1100) was performed at 1,5mL/min at 30C. A standard curve from
powder samples was used to quantify tablet samples.
A.2.6 Cipro Excipient Testing
Cipro powder samples at 0,0025mg/mL were spiked with 5, 10, 25, and 50% excipient
(inactive add-ins) by weight. Then, samples were filtered through a 0,22 um cellulose
acetate syringe filter and the assay was performed as described above. The normalized
fluorescence was calculated by dividing the fluorescence of the cipro solution with
excipient to the fluorescence of a control sample containing just cipro powder.
A.2.7 Enro Assay Procedure: Powder
Enro powder (Sigma) was dissolved in acetate buffer (pH 5) at 10 mg/mL (standard
solution) and diluted to 0,005 mg/mL, 0,0025mg/mL and 0,00125 mg/mL. From this
point, the cipro assay procedure was followed.
A.2.8 Enro Assay Procedure: Tablet
Enro tablets (15, 50, and 150 mg) were dissolved in 50 mL of acetate buffer (pH 5) and
filtered through a 0,22 um cellulose acetate syringe filter (Abulo). The enro solutions
were then diluted to the same concentrations explained above and the procedure for
powder was followed exactly.
A.2.9 Guanine Assay Procedure
Guanine (Sigma) was dissolved in deionized water at 10 mg/mL (standard solution)
and diluted to 0,005 mg/mL, 0,0025mg/mL and 0,00125 mg/mL. Autofluorescence
(excitation 275, emission 450) was detected on the spectrophotometer (Molecular De-
vices SpectraMax M5 Microplate Reader). The assay was then performed by mixing
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probe solution, containing methyl cellulose, palladium chloride and acetate buffer at
pH 5, with the guanine solutions at a 1:1 volume ratio. Autofluorescence was detected
again on the spectrophotometer for 10 minutes, every 10 seconds. These experiments
were conducted in a 96-well plate system.
A.3 Results
Cipro autofluorescence is diminished in the presence of metal ions and surfactant
by a mechanism explained elsewhere (Wang et al., 2014). This phenomenon can be
exploited to quantify the amount of cipro in solution by comparing fluorescence values
between samples of known and unknown concentrations.
Cipro powder is linearly fluorescent in the range between 0,00125 mg/mL and
0,005 mg/mL cipro. With the addition of probe, this linear signal continues but with
quenched fluorescence, shown in A·1. When compared to cipro tablets dissolved at
the same concentrations, cipro powder shows comparable fluorescence.
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Figure A·1: LLinear fluorescence range before and after quenching.
Cipro auto-fluorescence is quenched after addition of probe, shown
for both powder samples (dark gray) and tablet samples (light gray).
Square data points show the cipro samples’ fluorescence without probe,
while circular data points show the cipro fluorescence with probe. Both
the tablet and powder samples show a linear fluorescence profile be-
tween 0.005mg/mL cipro and 0.00125mg/mL cipro, with a correlation
coefficient of 0.999. Error bars represent the standard deviation over 3
trials.
For quantification, a standard powder solution was prepared and diluted as de-
scribed above. A tablet solution was filtered and diluted to various concentrations,
also described above. The probe solution was added to both the powder and tablet
samples and fluorescence was monitored. The linear region of fluorescence from the
powder samples was used to construct a line of best fit, and the tablet solutions were
quantified using this line. For Brand A, Brand B, and Brand C, we used a scaling
factor of 0,70, 0,82, and 0,86, respectively. This was used to scale the tablet samples
up to the powder samples so that the powder line of best fit could be used. The dif-
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ference in fluorescent signal between powder and tablet was likely due to excipients in
the tablet. But, because tablet formulations are proprietary, it is hard to identify and
test the excipients specifically in these three tablet types that could be interfering in
the assay and causing the need for a scaling factor.
The three tablet types tested, as shown in A·2, showed an average error of 2,4%
compared to HPLC, the gold-standard for tablet testing. The 500 mg Brand A tablet
quantified at 482 mg using the fluorescence assay and 460 mg using HPLC. The 500
mg Brand B tablet quantified at 503 mg using the fluorescence assay and 525 mg
using HPLC. The Brand C tablet quantified at 519 mg using the fluorescence assay
and 531 mg using HPLC. Therefore, for the Brand A tablet, the error compared to
HPLC was 3,3% while for Brand B it was 1,6% and Brand C it was 2,2%. HPLC was
used as a gold-standard comparison for validation of the assay demonstrated here.
Future use of this assay does not rely on HPLC testing.
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Figure A·2: Cipro quantification of three tablet brands. The pack-
age indication (shown in light gray) compared to gold-standard HPLC
(black) and the fluorescence assay demonstrated here (medium gray).
The three tablet types contain cipro within 10% of the package indi-
cation, according to HPLC analysis. The fluorescence assay correlates
to HPLC with an average error of 2.4%. The error bars for the HPLC
show the standard deviation over 3 trials. Error bars for the fluores-
cence assay show the standard deviation over 18,17, and 12 trials from
left to right.
To this end, we conducted specificity testing with the most commonly published
excipients found in cipro formulations (Cip, 2006; Cip, ; Li et al., 2007; Roy, 2012).
We tested the effects of added cellulose, hypromellose, cornstarch, povidone k30, and
magnesium stearate, using the procedure outlined above. As shown in A·3 none of
these excipients greatly affect the cipro fluorescent signal, even in the presence of up
to 50% excipient.
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Figure A·3: Cipro excipient testing. Fluorescent signal from the assay
run with added excipient is normalized to a fluorescent signal from the
assay run with pure cipro, y-axis. Data represents the mean +/- the
standard deviation, error bars over three trials are too small to be
visualized. The excipients tested showed no major effect on the assay
fluorescence as the signal from samples with added excipient was similar
to signal from samples without excipient.
Enro, another fluoroquinolone similar in structure to cipro, is used extensively
in veterinary medicine. We adapted our assay to quantify enro by changing the
solvent for dissolving the tablet. Because enro is not water soluble, we instead used
acetate buffer for dissolution. Then, following the assay procedure described above,
we quantified 3 different dosage forms of veterinary enrofloxacin Brand D with an
average error of 4,5% measured against package indication. 9 samples from each of
the 15 mg and 50 mg tablets were quantified, while 6 samples from 150 mg tablets were
quantified, shown in A·4. The 15 mg Brand D tablet quantified using the fluorescence
assay as 15 mg, while the 50 mg and 150 mg tablets quantified at 49mg and 156 mg
respectively.
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Figure A·4: Enro quantification of three tablet dosages. The pack-
age indication (shown in light gray) compared the fluorescence assay
demonstrated here (medium gray). The fluorescence assay correlates to
the package indication with an average error of 4.5%. Error bars show
the standard deviation over 9,9 and 6 trials from left to right.
To ensure our assay was specific to fluoroquinolone drugs and would not detect
other molecules with similar absorption and emission spectra, we tested this assay
using guanine instead of cipro. Guanine, like cipro, shows an absorption peak at 275
nm and a corresponding emission peak at 450 nm. As shown in A·5, the fluorescence
of guanine increases upon addition of probe: this is opposite the cipro quenching.
Therefore, the quenching trend can be used to discriminate fluoroquinolones from
other similarly absorbing and fluorescing molecules.
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Figure A·5: Guanine fluorescence as a function of concentration. The
cipro assay was run with guanine samples (no added cipro) as a nega-
tive control. Square data points show the fluorescence of the guanine
samples without probe, while circular data points show fluorescence
of the guanine samples with probe. The guanine fluorescence is in-
creased upon addition of probe, as opposed to cipro fluorescence which
is quenched.
A.4 Discussion
In this study, we demonstrate the use of a quantitative assay for cipro formulations.
The widespread availability and use of substandard and counterfeit cipro has been
linked to the increased risk of antimicrobial resistance, specifically in low-resource set-
tings where there is a lack of regulatory policies governing appropriate manufacturing
and quality assurance. The current methods used to assess the quality of cipro are
prohibitively expensive for applications in low-resource settings (e.g. HPLC) or do
not provide quantitative data (e.g. MiniLab). Additionally, many newer lab-based
assays that have been developed still require extensive sample preparation, utilize
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dangerous reagents, and rely on expensive equipment and tools. Therefore, there are
a lack of tests that can be easily translated to the field and assess quality of cipro in
a quantitative manner.
To fill this gap, we have developed an assay to test for the amount of cipro in
pharmaceutical formulations. We validated our assay by testing with three brands
of cipro, showing an average of 2,4% error from the HPLC gold standard. Though
showing great alignment with HPLC, the assay demonstrated here functions indepen-
dently of HPLC- a quality imperative for field testing of pharmaceutical formulations.
Additionally, we showed that our assay will not be affected by many of the common
excipients in cipro formulations, specifically cellulose, hypromellose, cornstarch, povi-
done k30, and magnesium stearate. That being said, additional excipient testing
would be useful to identify excipients in tablets that do cause a change in assay fluo-
rescence. This could help to identify which tablet types will and will not need scaling
factors for quantification.
We also extended this assay to quantify enro formulations in 3 common dosages
with an average error of 4.5% measured against the package indication. With further
development efforts, this assay could be adapted to other fluoroquinolones, such as
norfloxacin and pefloxacin, as well. We ensured the specificity of our assay for fluoro-
quinolones by conducting cross reactivity tests with guanine, a molecule that absorbs
and fluoresces similarly to cipro. Although this assay can readily assess the quality
of cipro or enro from different formulations, it cannot discriminate between differ-
ent fluoroquinolones if the identity is not known. Therefore, it would be necessary
to know which fluoroquinolone is in the tablet being assessed. Additionally, we did
not test this assay with substandard or counterfeit medications, as none were readily
available to us. In future studies, we could do a more thorough collection and testing
of ciprofloxacin tablets from around the world.
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Despite this challenge, these assays show great promise in assessing the quality
of cipro and enro formulations in the field, as they can be adapted to portable mi-
crofluidic platforms capable of assessing drug quality (Desai and Zaman, 2015; Ho
et al., 2015) At this point, these assays have been demonstrated as a proof-of-concept,
but further development is needed to fully translate these assays to the previously
mentioned microfluidic platforms. These assays can also be used to help strengthen
the evidence linking poor quality medicines and AMR by surveying poor quality
ciprofloxacin in the field. With these quantitative assays in hand, substandard and
counterfeit cipro formulations can be identified and removed from circulation, thereby
increasing the quality of medicines while decreasing poor patient outcomes and the
acceleration of resistance.
A.5 Conclusion
This study demonstrates a quantitative fluorescence assay for cipro that can be incor-
porated at the point-of-care through our lab’s pharmaceutical screening technology,
PharmaChk. Cipro tablets of three different brands were quantified with an aver-
age error of 2,4%. The signal was not affected by the addition of 5 common cipro
tablet excipients. Additionally, this assay was extended to quantify enro tablets of 3
concentrations with an average error of 4.5%.
This assay can be used to assess the quality of cipro tablets in the field and identify
substandard tablets, potentially helping to remove those tablets from circulation and
decrease acceleration of AMR to cipro.
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